[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fvGfPpOYqeY_t6NWRyg0RfTqMLzx8CVWwyu633J_mkZk":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":87,"rows":94},"Dartmouth-Hitchcock Medical Center",[4],481,false,82,14,128675,29,347,[14,17,20,23,25,27,30,33],{"name":15,"count":16},"Schizophrenia",27,{"name":18,"count":19},"Breast Cancer",26,{"name":21,"count":22},"Schizoaffective Disorder",17,{"name":24,"count":9},"Depression",{"name":26,"count":9},"Bipolar Disorder",{"name":28,"count":29},"Obesity",13,{"name":31,"count":32},"Epilepsy",12,{"name":34,"count":35},"Cancer",11,[37,42,47,52,57,62,67,72,77,82],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT03480360","Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression","2025-02-14","Cyclophosphamide",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT07071038","Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients","2026-08-05","Switch",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT05512039","Reduced-dose Botox for Urgency Incontinence Among Elder Females","2026-09-01","Botox 50 Unit",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT06793644","Study of ICG Fluorescence Imaging in Open Fracture and Infection Patients","2026-10","Immunofluorescence Imaging",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT07201376","Assessment of Skin Lesions Using a Tissue Oxygen Imager Based on Protoporphyrin IX (PPIX) Fluorescence. This is an Open-label, Non-randomized, Feasibility Study That Includes a One-time Application of an FDA Approved Medication Followed by Local Imaging for Benign Skin Growth and Lesions Clinically","2026-11","Ameluz 10% Topical Gel",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT04678895","Low-Dose Naltrexone for the Treatment of Painful Diabetic Neuropathy","2026-12","Naltrexone",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT06777511","Advancing Antimicrobial Photodynamic Therapy to Prevent Infection in Osseointegrated Prosthesis Patients","2027-03-01","5-aminolevulinic acid",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT07592520","Flush, Lyse, Operate","2027-04","Intrapleural Saline with possible escalation to intraplerual alteplase and dornase.",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT07546617","In Vivo Imaging of the Olfactory Epithelium Using Confocal Laser Endomicroscopy","2027-04-30","Fluorescein injection, USP 10%",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT05716516","STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)","2027-05","Estradiol",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,120,148,196,231,249,319,358,393,442,484,504,522,540,558,576,599,624,642,669,687,705,723,749,769,833,856,879,902,924,951,975,1001,1027,1045,1071,1094,1119,1147,1165,1183,1208,1234,1252,1276,1300,1318,1342,1369,1393,1421,1439,1464,1489,1515,1533,1558,1576,1594,1619,1666,1713,1751,1794,1830,1874,1909,1937,1971,2004,2033,2055,2080,2098,2123,2141,2159,2177,2195,2220,2238,2262,2280,2298,2316,2343,2361,2379,2397,2415,2440,2458,2476,2494,2512,2536,2560,2578,2600,2624,2649,2673,2697,2715,2733,2751,2769,2793,2811,2834,2859,2891,2924,2952,2974,2996,3018,3036,3059,3077,3095,3113,3137,3155,3173,3197,3215,3233,3251,3269,3287,3305,3328,3346,3368,3386,3409,3427,3445,3463,3486,3511,3535,3557,3581,3620,3657,3701,3723,3752,3777,3799,3834,3859,3877,3895,3913,3936,3960,3982,4005,4023,4047,4072,4094,4112,4134,4159,4177,4201,4219,4241,4259,4277,4295,4313],{"intervention":76,"totalTrials":96,"cells":97},1,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":107,"NA":118},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":100},[],{"trials":106,"activeCount":100},[],{"trials":108,"activeCount":96,"soonestReadout":75},[109],{"nctId":73,"briefTitle":74,"status":110,"phases":111,"primaryCompletion":75,"completion":75,"start":112,"enrollment":113,"conditions":114,"interventions":117},"NOT_YET_RECRUITING",[92],"2026-04",30,[115,116],"Complicated Parapneumonic Effusion","Empyema, Pleural",[76],{"trials":119,"activeCount":100},[],{"intervention":121,"totalTrials":96,"cells":122},"Lidocaine in Saline",{"EARLY_PHASE1":123,"PHASE1":125,"PHASE2":127,"PHASE3":129,"PHASE4":131,"NA":146},{"trials":124,"activeCount":100},[],{"trials":126,"activeCount":100},[],{"trials":128,"activeCount":100},[],{"trials":130,"activeCount":100},[],{"trials":132,"activeCount":96,"soonestReadout":137},[133],{"nctId":134,"briefTitle":135,"status":110,"phases":136,"primaryCompletion":137,"completion":137,"start":138,"enrollment":139,"conditions":140,"interventions":144},"NCT06792474","Influence of Lidocaine Infusion on Motor Evoked Potential Thresholds",[92],"2027-08","2026-08",44,[141,142,143],"Spinal Disease","Anesthesia","Post Operative Pain",[121,145],"Normal saline",{"trials":147,"activeCount":100},[],{"intervention":145,"totalTrials":149,"cells":150},3,{"EARLY_PHASE1":151,"PHASE1":153,"PHASE2":155,"PHASE3":173,"PHASE4":175,"NA":181},{"trials":152,"activeCount":100},[],{"trials":154,"activeCount":100},[],{"trials":156,"activeCount":100},[157],{"nctId":158,"briefTitle":159,"status":160,"phases":161,"primaryCompletion":162,"completion":163,"start":164,"enrollment":100,"conditions":165,"interventions":170},"NCT03446599","Hemodynamic Effects of Methylene Blue vs Hydroxocobalamin in Patients at Risk of Vasoplegia During Cardiac Surgery","WITHDRAWN",[90],"2020-05","2020-06-30","2019-11",[166,167,168,169],"Vasoplegia","Hypotension","Coronary Artery Disease","Cardiac Valve Disease",[171,172,145],"Hydroxocobalamin","Methylene Blue",{"trials":174,"activeCount":100},[],{"trials":176,"activeCount":96,"soonestReadout":137},[177],{"nctId":134,"briefTitle":135,"status":110,"phases":178,"primaryCompletion":137,"completion":137,"start":138,"enrollment":139,"conditions":179,"interventions":180},[92],[141,142,143],[121,145],{"trials":182,"activeCount":100},[183],{"nctId":184,"briefTitle":185,"status":186,"phases":187,"primaryCompletion":188,"completion":189,"start":190,"enrollment":9,"conditions":191,"interventions":193},"NCT00958919","Role of Endorphins in Perception of Dyspnea With Resistive Loading in Chronic Obstructive Pulmonary Disease (COPD)","COMPLETED",[93],"2010-08","2010-10","2009-08",[192],"Chronic Obstructive Pulmonary Disease",[194,195],"naloxone","normal saline",{"intervention":197,"totalTrials":96,"cells":198},"Tacrolimus",{"EARLY_PHASE1":199,"PHASE1":201,"PHASE2":203,"PHASE3":205,"PHASE4":227,"NA":229},{"trials":200,"activeCount":100},[],{"trials":202,"activeCount":100},[],{"trials":204,"activeCount":100},[],{"trials":206,"activeCount":96,"soonestReadout":40},[207],{"nctId":38,"briefTitle":39,"status":208,"phases":209,"primaryCompletion":40,"completion":210,"start":211,"enrollment":212,"conditions":213,"interventions":223},"ACTIVE_NOT_RECRUITING",[91],"2026-10-17","2018-03-28",21,[214,215,216,217,218,219,220,221,222],"Acute Myeloid Leukemia","Chronic Lymphocytic Leukemia","Chronic Myeloid Leukemia","Myelodysplasia","Myeloproliferative Disorder","Myelofibrosis","Lymphoma","Lymphoma, Non-Hodgkin","Plasma Cell Disorder",[41,224,197,225,226],"Fludarabine","cellcept","g-csf",{"trials":228,"activeCount":100},[],{"trials":230,"activeCount":100},[],{"intervention":225,"totalTrials":96,"cells":232},{"EARLY_PHASE1":233,"PHASE1":235,"PHASE2":237,"PHASE3":239,"PHASE4":245,"NA":247},{"trials":234,"activeCount":100},[],{"trials":236,"activeCount":100},[],{"trials":238,"activeCount":100},[],{"trials":240,"activeCount":96,"soonestReadout":40},[241],{"nctId":38,"briefTitle":39,"status":208,"phases":242,"primaryCompletion":40,"completion":210,"start":211,"enrollment":212,"conditions":243,"interventions":244},[91],[214,215,216,217,218,219,220,221,222],[41,224,197,225,226],{"trials":246,"activeCount":100},[],{"trials":248,"activeCount":100},[],{"intervention":41,"totalTrials":250,"cells":251},5,{"EARLY_PHASE1":252,"PHASE1":254,"PHASE2":256,"PHASE3":297,"PHASE4":303,"NA":305},{"trials":253,"activeCount":100},[],{"trials":255,"activeCount":100},[],{"trials":257,"activeCount":100},[258,269,284],{"nctId":259,"briefTitle":260,"status":186,"phases":261,"primaryCompletion":262,"completion":263,"start":264,"enrollment":265,"conditions":266,"interventions":268},"NCT02139280","Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy",[90],"2019-07","2020-09","2013-12",58,[267],"Hematologic Malignancies",[41],{"nctId":270,"briefTitle":271,"status":186,"phases":272,"primaryCompletion":273,"completion":274,"start":275,"enrollment":276,"conditions":277,"interventions":279},"NCT00085423","Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma",[90],"2008-12","2010-02","2004-02",20,[278],"Melanoma (Skin)",[280,281,282,283],"aldesleukin","sargramostim","cyclophosphamide","fludarabine phosphate",{"nctId":285,"briefTitle":286,"status":287,"phases":288,"primaryCompletion":289,"completion":289,"start":290,"enrollment":291,"conditions":292,"interventions":294},"NCT01542255","Metronomic Therapy in Patients With Metastatic Melanoma","TERMINATED",[90],"2013-01","2010-06",7,[293],"Metastatic Melanoma",[295,41,296],"vinblastine","dacarbazine",{"trials":298,"activeCount":96,"soonestReadout":40},[299],{"nctId":38,"briefTitle":39,"status":208,"phases":300,"primaryCompletion":40,"completion":210,"start":211,"enrollment":212,"conditions":301,"interventions":302},[91],[214,215,216,217,218,219,220,221,222],[41,224,197,225,226],{"trials":304,"activeCount":100},[],{"trials":306,"activeCount":100},[307],{"nctId":308,"briefTitle":309,"status":186,"phases":310,"primaryCompletion":311,"completion":311,"start":312,"enrollment":313,"conditions":314,"interventions":315},"NCT00741455","Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies",[93],"2020-05-01","2004-06",18,[267],[316,224,282,317,318],"G-CSF","Cyclosporine","Methotrexate",{"intervention":224,"totalTrials":149,"cells":320},{"EARLY_PHASE1":321,"PHASE1":323,"PHASE2":342,"PHASE3":344,"PHASE4":350,"NA":352},{"trials":322,"activeCount":100},[],{"trials":324,"activeCount":100},[325],{"nctId":326,"briefTitle":327,"status":186,"phases":328,"primaryCompletion":329,"completion":330,"start":331,"enrollment":276,"conditions":332,"interventions":339},"NCT02916979","Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG",[89],"2019-06-07","2022-02-11","2016-09-06",[333,334,335,219,336,337,338],"Leukemia, Lymphoid","Leukemia, Myeloid","Myelodysplastic Syndromes","Lymphoma, Malignant","Multiple Myeloma","Waldenstrom Macroglobulinemia",[224,340,341,318],"Busulfan","Rabbit ATG",{"trials":343,"activeCount":100},[],{"trials":345,"activeCount":96,"soonestReadout":40},[346],{"nctId":38,"briefTitle":39,"status":208,"phases":347,"primaryCompletion":40,"completion":210,"start":211,"enrollment":212,"conditions":348,"interventions":349},[91],[214,215,216,217,218,219,220,221,222],[41,224,197,225,226],{"trials":351,"activeCount":100},[],{"trials":353,"activeCount":100},[354],{"nctId":308,"briefTitle":309,"status":186,"phases":355,"primaryCompletion":311,"completion":311,"start":312,"enrollment":313,"conditions":356,"interventions":357},[93],[267],[316,224,282,317,318],{"intervention":316,"totalTrials":149,"cells":359},{"EARLY_PHASE1":360,"PHASE1":362,"PHASE2":364,"PHASE3":366,"PHASE4":385,"NA":387},{"trials":361,"activeCount":100},[],{"trials":363,"activeCount":100},[],{"trials":365,"activeCount":100},[],{"trials":367,"activeCount":96,"soonestReadout":40},[368,372],{"nctId":38,"briefTitle":39,"status":208,"phases":369,"primaryCompletion":40,"completion":210,"start":211,"enrollment":212,"conditions":370,"interventions":371},[91],[214,215,216,217,218,219,220,221,222],[41,224,197,225,226],{"nctId":373,"briefTitle":374,"status":287,"phases":375,"primaryCompletion":376,"completion":376,"start":377,"enrollment":378,"conditions":379,"interventions":381},"NCT00169104","Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function",[90,91],"2009-03","2002-07",23,[380],"Metastatic Breast Cancer",[316,382,383,316,384],"trastuzumab","vinorelbine","saline placebo",{"trials":386,"activeCount":100},[],{"trials":388,"activeCount":100},[389],{"nctId":308,"briefTitle":309,"status":186,"phases":390,"primaryCompletion":311,"completion":311,"start":312,"enrollment":313,"conditions":391,"interventions":392},[93],[267],[316,224,282,317,318],{"intervention":394,"totalTrials":149,"cells":395},"Capecitabine",{"EARLY_PHASE1":396,"PHASE1":398,"PHASE2":419,"PHASE3":436,"PHASE4":438,"NA":440},{"trials":397,"activeCount":100},[],{"trials":399,"activeCount":100},[400,410],{"nctId":401,"briefTitle":402,"status":186,"phases":403,"primaryCompletion":404,"completion":405,"start":406,"enrollment":32,"conditions":407,"interventions":408},"NCT00169000","Safety Study of a New Schedule of Capecitabine and Docetaxel to Treat Cancers",[89],"2005-09","2006-03","2003-01",[380],[394,409],"Docetaxel",{"nctId":411,"briefTitle":412,"status":186,"phases":413,"primaryCompletion":414,"completion":414,"start":415,"enrollment":139,"conditions":416,"interventions":418},"NCT00153881","Docetaxel and Carboplatin Followed by Oral Capecitabine, Docetaxel and Radiation for Esophageal Cancer",[89],"2013-09","2000-02",[417],"Esophageal Neoplasms",[394],{"trials":420,"activeCount":96,"soonestReadout":426},[421],{"nctId":422,"briefTitle":423,"status":424,"phases":425,"primaryCompletion":426,"completion":427,"start":428,"enrollment":429,"conditions":430,"interventions":433},"NCT06134375","A Study of Tetrathiomolybdate (TM) Plus Capecitabine","RECRUITING",[89,90],"2031-06-26","2036-06-26","2024-11-26",204,[431,432],"Triple Negative Breast Cancer","Residual Disease",[434,394,435],"Tetrathiomolybdate","Pembrolizumab",{"trials":437,"activeCount":100},[],{"trials":439,"activeCount":100},[],{"trials":441,"activeCount":100},[],{"intervention":443,"totalTrials":444,"cells":445},"Fulvestrant",2,{"EARLY_PHASE1":446,"PHASE1":448,"PHASE2":461,"PHASE3":478,"PHASE4":480,"NA":482},{"trials":447,"activeCount":100},[],{"trials":449,"activeCount":100},[450],{"nctId":451,"briefTitle":452,"status":287,"phases":453,"primaryCompletion":454,"completion":455,"start":456,"enrollment":457,"conditions":458,"interventions":459},"NCT02384746","Phase I Study of the Combination of MLN9708 and Fulvestrant",[89],"2018-04-12","2018-06-10","2015-06-02",9,[18],[443,460],"MLN9708",{"trials":462,"activeCount":96,"soonestReadout":467},[463],{"nctId":464,"briefTitle":465,"status":424,"phases":466,"primaryCompletion":467,"completion":468,"start":469,"enrollment":470,"conditions":471,"interventions":473},"NCT05933395","Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4\u002F6 Inhibitor",[90],"2030-10","2031-10","2024-09-23",135,[472],"Advanced Breast Cancer",[443,474,475,476,477],"Neratinib","Alpelisib","Everolimus","Abemaciclib",{"trials":479,"activeCount":100},[],{"trials":481,"activeCount":100},[],{"trials":483,"activeCount":100},[],{"intervention":86,"totalTrials":96,"cells":485},{"EARLY_PHASE1":486,"PHASE1":488,"PHASE2":490,"PHASE3":498,"PHASE4":500,"NA":502},{"trials":487,"activeCount":100},[],{"trials":489,"activeCount":100},[],{"trials":491,"activeCount":96,"soonestReadout":85},[492],{"nctId":83,"briefTitle":84,"status":424,"phases":493,"primaryCompletion":85,"completion":85,"start":494,"enrollment":495,"conditions":496,"interventions":497},[90],"2023-05-04",36,[380],[86],{"trials":499,"activeCount":100},[],{"trials":501,"activeCount":100},[],{"trials":503,"activeCount":100},[],{"intervention":474,"totalTrials":96,"cells":505},{"EARLY_PHASE1":506,"PHASE1":508,"PHASE2":510,"PHASE3":516,"PHASE4":518,"NA":520},{"trials":507,"activeCount":100},[],{"trials":509,"activeCount":100},[],{"trials":511,"activeCount":96,"soonestReadout":467},[512],{"nctId":464,"briefTitle":465,"status":424,"phases":513,"primaryCompletion":467,"completion":468,"start":469,"enrollment":470,"conditions":514,"interventions":515},[90],[472],[443,474,475,476,477],{"trials":517,"activeCount":100},[],{"trials":519,"activeCount":100},[],{"trials":521,"activeCount":100},[],{"intervention":475,"totalTrials":96,"cells":523},{"EARLY_PHASE1":524,"PHASE1":526,"PHASE2":528,"PHASE3":534,"PHASE4":536,"NA":538},{"trials":525,"activeCount":100},[],{"trials":527,"activeCount":100},[],{"trials":529,"activeCount":96,"soonestReadout":467},[530],{"nctId":464,"briefTitle":465,"status":424,"phases":531,"primaryCompletion":467,"completion":468,"start":469,"enrollment":470,"conditions":532,"interventions":533},[90],[472],[443,474,475,476,477],{"trials":535,"activeCount":100},[],{"trials":537,"activeCount":100},[],{"trials":539,"activeCount":100},[],{"intervention":476,"totalTrials":96,"cells":541},{"EARLY_PHASE1":542,"PHASE1":544,"PHASE2":546,"PHASE3":552,"PHASE4":554,"NA":556},{"trials":543,"activeCount":100},[],{"trials":545,"activeCount":100},[],{"trials":547,"activeCount":96,"soonestReadout":467},[548],{"nctId":464,"briefTitle":465,"status":424,"phases":549,"primaryCompletion":467,"completion":468,"start":469,"enrollment":470,"conditions":550,"interventions":551},[90],[472],[443,474,475,476,477],{"trials":553,"activeCount":100},[],{"trials":555,"activeCount":100},[],{"trials":557,"activeCount":100},[],{"intervention":477,"totalTrials":96,"cells":559},{"EARLY_PHASE1":560,"PHASE1":562,"PHASE2":564,"PHASE3":570,"PHASE4":572,"NA":574},{"trials":561,"activeCount":100},[],{"trials":563,"activeCount":100},[],{"trials":565,"activeCount":96,"soonestReadout":467},[566],{"nctId":464,"briefTitle":465,"status":424,"phases":567,"primaryCompletion":467,"completion":468,"start":469,"enrollment":470,"conditions":568,"interventions":569},[90],[472],[443,474,475,476,477],{"trials":571,"activeCount":100},[],{"trials":573,"activeCount":100},[],{"trials":575,"activeCount":100},[],{"intervention":46,"totalTrials":96,"cells":577},{"EARLY_PHASE1":578,"PHASE1":580,"PHASE2":582,"PHASE3":593,"PHASE4":595,"NA":597},{"trials":579,"activeCount":100},[],{"trials":581,"activeCount":100},[],{"trials":583,"activeCount":96,"soonestReadout":45},[584],{"nctId":43,"briefTitle":44,"status":424,"phases":585,"primaryCompletion":45,"completion":586,"start":587,"enrollment":588,"conditions":589,"interventions":592},[90],"2027-08-05","2025-10-17",62,[18,590,591],"Adjuvant Treatment","Early Stage Breast Cancer",[46],{"trials":594,"activeCount":100},[],{"trials":596,"activeCount":100},[],{"trials":598,"activeCount":100},[],{"intervention":51,"totalTrials":96,"cells":600},{"EARLY_PHASE1":601,"PHASE1":603,"PHASE2":605,"PHASE3":618,"PHASE4":620,"NA":622},{"trials":602,"activeCount":100},[],{"trials":604,"activeCount":100},[],{"trials":606,"activeCount":96,"soonestReadout":50},[607],{"nctId":48,"briefTitle":49,"status":208,"phases":608,"primaryCompletion":50,"completion":609,"start":610,"enrollment":611,"conditions":612,"interventions":616},[89,90],"2027-01-01","2023-05-12",376,[613,614,615],"Overactive Bladder","Urinary Incontinence in Old Age","Urgency Urinary Incontinence",[51,617],"Botox 100 Unit",{"trials":619,"activeCount":100},[],{"trials":621,"activeCount":100},[],{"trials":623,"activeCount":100},[],{"intervention":617,"totalTrials":96,"cells":625},{"EARLY_PHASE1":626,"PHASE1":628,"PHASE2":630,"PHASE3":636,"PHASE4":638,"NA":640},{"trials":627,"activeCount":100},[],{"trials":629,"activeCount":100},[],{"trials":631,"activeCount":96,"soonestReadout":50},[632],{"nctId":48,"briefTitle":49,"status":208,"phases":633,"primaryCompletion":50,"completion":609,"start":610,"enrollment":611,"conditions":634,"interventions":635},[89,90],[613,614,615],[51,617],{"trials":637,"activeCount":100},[],{"trials":639,"activeCount":100},[],{"trials":641,"activeCount":100},[],{"intervention":643,"totalTrials":96,"cells":644},"Nab-paclitaxel + Gemcitabine",{"EARLY_PHASE1":645,"PHASE1":647,"PHASE2":649,"PHASE3":663,"PHASE4":665,"NA":667},{"trials":646,"activeCount":100},[],{"trials":648,"activeCount":100},[],{"trials":650,"activeCount":96,"soonestReadout":655},[651],{"nctId":652,"briefTitle":653,"status":424,"phases":654,"primaryCompletion":655,"completion":656,"start":657,"enrollment":658,"conditions":659,"interventions":661},"NCT07043270","24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC",[90],"2028-07-01","2029-07-01","2025-09-29",35,[660],"Pancreas Adenocarcinoma",[643,662],"modified FOLFIRINOX",{"trials":664,"activeCount":100},[],{"trials":666,"activeCount":100},[],{"trials":668,"activeCount":100},[],{"intervention":662,"totalTrials":96,"cells":670},{"EARLY_PHASE1":671,"PHASE1":673,"PHASE2":675,"PHASE3":681,"PHASE4":683,"NA":685},{"trials":672,"activeCount":100},[],{"trials":674,"activeCount":100},[],{"trials":676,"activeCount":96,"soonestReadout":655},[677],{"nctId":652,"briefTitle":653,"status":424,"phases":678,"primaryCompletion":655,"completion":656,"start":657,"enrollment":658,"conditions":679,"interventions":680},[90],[660],[643,662],{"trials":682,"activeCount":100},[],{"trials":684,"activeCount":100},[],{"trials":686,"activeCount":100},[],{"intervention":434,"totalTrials":96,"cells":688},{"EARLY_PHASE1":689,"PHASE1":691,"PHASE2":693,"PHASE3":699,"PHASE4":701,"NA":703},{"trials":690,"activeCount":100},[],{"trials":692,"activeCount":100},[],{"trials":694,"activeCount":96,"soonestReadout":426},[695],{"nctId":422,"briefTitle":423,"status":424,"phases":696,"primaryCompletion":426,"completion":427,"start":428,"enrollment":429,"conditions":697,"interventions":698},[89,90],[431,432],[434,394,435],{"trials":700,"activeCount":100},[],{"trials":702,"activeCount":100},[],{"trials":704,"activeCount":100},[],{"intervention":435,"totalTrials":96,"cells":706},{"EARLY_PHASE1":707,"PHASE1":709,"PHASE2":711,"PHASE3":717,"PHASE4":719,"NA":721},{"trials":708,"activeCount":100},[],{"trials":710,"activeCount":100},[],{"trials":712,"activeCount":96,"soonestReadout":426},[713],{"nctId":422,"briefTitle":423,"status":424,"phases":714,"primaryCompletion":426,"completion":427,"start":428,"enrollment":429,"conditions":715,"interventions":716},[89,90],[431,432],[434,394,435],{"trials":718,"activeCount":100},[],{"trials":720,"activeCount":100},[],{"trials":722,"activeCount":100},[],{"intervention":724,"totalTrials":96,"cells":725},"Letrozole 2.5mg",{"EARLY_PHASE1":726,"PHASE1":728,"PHASE2":730,"PHASE3":743,"PHASE4":745,"NA":747},{"trials":727,"activeCount":100},[],{"trials":729,"activeCount":100},[],{"trials":731,"activeCount":96,"soonestReadout":736},[732],{"nctId":733,"briefTitle":734,"status":208,"phases":735,"primaryCompletion":736,"completion":737,"start":738,"enrollment":739,"conditions":740,"interventions":742},"NCT04568616","Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)",[90],"2028-04-02","2029-08-13","2021-08-13",178,[18,741],"ER Positive Breast Cancer",[724],{"trials":744,"activeCount":100},[],{"trials":746,"activeCount":100},[],{"trials":748,"activeCount":100},[],{"intervention":66,"totalTrials":96,"cells":750},{"EARLY_PHASE1":751,"PHASE1":753,"PHASE2":755,"PHASE3":763,"PHASE4":765,"NA":767},{"trials":752,"activeCount":100},[],{"trials":754,"activeCount":100},[],{"trials":756,"activeCount":96,"soonestReadout":65},[757],{"nctId":63,"briefTitle":64,"status":424,"phases":758,"primaryCompletion":65,"completion":65,"start":759,"enrollment":658,"conditions":760,"interventions":762},[90],"2020-12-22",[761],"Painful Diabetic Neuropathy",[66],{"trials":764,"activeCount":100},[],{"trials":766,"activeCount":100},[],{"trials":768,"activeCount":100},[],{"intervention":770,"totalTrials":250,"cells":771},"ABY-029",{"EARLY_PHASE1":772,"PHASE1":801,"PHASE2":825,"PHASE3":827,"PHASE4":829,"NA":831},{"trials":773,"activeCount":100},[774,783,792],{"nctId":775,"briefTitle":776,"status":186,"phases":777,"primaryCompletion":778,"completion":778,"start":779,"enrollment":32,"conditions":780,"interventions":782},"NCT03154411","A Microdose Evaluation Study of ABY-029 in Primary Sarcoma",[88],"2020-12-10","2017-08-30",[781],"Primary Soft-tissue Sarcoma",[770],{"nctId":784,"briefTitle":785,"status":186,"phases":786,"primaryCompletion":787,"completion":787,"start":788,"enrollment":32,"conditions":789,"interventions":791},"NCT03282461","A Microdose Evaluation Study of ABY-029 in Head and Neck Oncology Surgery",[88],"2020-12-18","2018-01-24",[790],"Head and Neck Cancer",[770],{"nctId":793,"briefTitle":794,"status":186,"phases":795,"primaryCompletion":796,"completion":796,"start":797,"enrollment":9,"conditions":798,"interventions":800},"NCT02901925","A Microdose Evaluation Study of ABY-029 in Recurrent Glioma",[88],"2021-06-29","2017-02-13",[799],"Glioma",[770],{"trials":802,"activeCount":444,"soonestReadout":807},[803,814],{"nctId":804,"briefTitle":805,"status":110,"phases":806,"primaryCompletion":807,"completion":808,"start":809,"enrollment":810,"conditions":811,"interventions":813},"NCT07279116","ABY-029 Head & Neck Trial",[89],"2027-12-31","2028-06-30","2026-06-30",24,[812],"Head and Neck Squamous Cell Carcinoma",[770],{"nctId":815,"briefTitle":816,"status":424,"phases":817,"primaryCompletion":818,"completion":819,"start":820,"enrollment":821,"conditions":822,"interventions":824},"NCT07063693","ABY-029 Glioma Trial",[89],"2028-07-31","2028-12-31","2026-02-17",33,[823],"Intracranial Tumor",[770],{"trials":826,"activeCount":100},[],{"trials":828,"activeCount":100},[],{"trials":830,"activeCount":100},[],{"trials":832,"activeCount":100},[],{"intervention":81,"totalTrials":96,"cells":834},{"EARLY_PHASE1":835,"PHASE1":837,"PHASE2":839,"PHASE3":841,"PHASE4":843,"NA":845},{"trials":836,"activeCount":100},[],{"trials":838,"activeCount":100},[],{"trials":840,"activeCount":100},[],{"trials":842,"activeCount":100},[],{"trials":844,"activeCount":100},[],{"trials":846,"activeCount":96,"soonestReadout":80},[847],{"nctId":78,"briefTitle":79,"status":110,"phases":848,"primaryCompletion":80,"completion":849,"start":850,"enrollment":495,"conditions":851,"interventions":855},[],"2027-07-31","2026-07-01",[852,853,854],"Endonasal Surgery","Endoscopic Sinus Surgery","Olfactory Dysfunction",[81],{"intervention":61,"totalTrials":96,"cells":857},{"EARLY_PHASE1":858,"PHASE1":860,"PHASE2":862,"PHASE3":864,"PHASE4":866,"NA":868},{"trials":859,"activeCount":100},[],{"trials":861,"activeCount":100},[],{"trials":863,"activeCount":100},[],{"trials":865,"activeCount":100},[],{"trials":867,"activeCount":100},[],{"trials":869,"activeCount":96,"soonestReadout":60},[870],{"nctId":58,"briefTitle":59,"status":424,"phases":871,"primaryCompletion":60,"completion":872,"start":873,"enrollment":874,"conditions":875,"interventions":878},[],"2027-11","2025-11-14",125,[876,877],"Non-Melanoma Skin Cancer (NMSC)","Benign Skin Growth",[61],{"intervention":56,"totalTrials":96,"cells":880},{"EARLY_PHASE1":881,"PHASE1":883,"PHASE2":885,"PHASE3":887,"PHASE4":889,"NA":891},{"trials":882,"activeCount":100},[],{"trials":884,"activeCount":100},[],{"trials":886,"activeCount":100},[],{"trials":888,"activeCount":100},[],{"trials":890,"activeCount":100},[],{"trials":892,"activeCount":96,"soonestReadout":55},[893],{"nctId":53,"briefTitle":54,"status":424,"phases":894,"primaryCompletion":55,"completion":895,"start":896,"enrollment":897,"conditions":898,"interventions":901},[],"2027-10","2025-06-10",10,[899,900],"Fractures, Bone","Trauma Injury",[56],{"intervention":71,"totalTrials":96,"cells":903},{"EARLY_PHASE1":904,"PHASE1":906,"PHASE2":908,"PHASE3":910,"PHASE4":912,"NA":914},{"trials":905,"activeCount":100},[],{"trials":907,"activeCount":100},[],{"trials":909,"activeCount":100},[],{"trials":911,"activeCount":100},[],{"trials":913,"activeCount":100},[],{"trials":915,"activeCount":96,"soonestReadout":70},[916],{"nctId":68,"briefTitle":69,"status":110,"phases":917,"primaryCompletion":70,"completion":918,"start":919,"enrollment":897,"conditions":920,"interventions":923},[],"2027-03-28","2026-03-01",[921,922],"Amputation","Osseointegration",[71],{"intervention":925,"totalTrials":96,"cells":926},"Quetiapine",{"EARLY_PHASE1":927,"PHASE1":929,"PHASE2":931,"PHASE3":933,"PHASE4":935,"NA":949},{"trials":928,"activeCount":100},[],{"trials":930,"activeCount":100},[],{"trials":932,"activeCount":100},[],{"trials":934,"activeCount":100},[],{"trials":936,"activeCount":100},[937],{"nctId":938,"briefTitle":939,"status":186,"phases":940,"primaryCompletion":941,"completion":942,"start":943,"enrollment":378,"conditions":944,"interventions":948},"NCT00156715","Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder",[92],"2006-09","2008-10","2004-03",[15,21,945,946,947],"Psychotic Disorder","Substance Abuse","Alcohol Abuse",[925],{"trials":950,"activeCount":100},[],{"intervention":952,"totalTrials":96,"cells":953},"aminolevulinic acid hydrochloride",{"EARLY_PHASE1":954,"PHASE1":956,"PHASE2":958,"PHASE3":960,"PHASE4":962,"NA":973},{"trials":955,"activeCount":100},[],{"trials":957,"activeCount":100},[],{"trials":959,"activeCount":100},[],{"trials":961,"activeCount":100},[],{"trials":963,"activeCount":100},[964],{"nctId":965,"briefTitle":966,"status":186,"phases":967,"primaryCompletion":968,"completion":968,"start":969,"enrollment":810,"conditions":970,"interventions":972},"NCT02409732","Photodynamic Therapy (PDT) With Levulan and Blue Light for the Treatment of Actinic Cheilitis",[92],"2017-07","2015-04",[971],"Actinic Cheilitis",[952],{"trials":974,"activeCount":100},[],{"intervention":976,"totalTrials":96,"cells":977},"lubiprostone",{"EARLY_PHASE1":978,"PHASE1":980,"PHASE2":982,"PHASE3":984,"PHASE4":986,"NA":999},{"trials":979,"activeCount":100},[],{"trials":981,"activeCount":100},[],{"trials":983,"activeCount":100},[],{"trials":985,"activeCount":100},[],{"trials":987,"activeCount":100},[988],{"nctId":989,"briefTitle":990,"status":186,"phases":991,"primaryCompletion":992,"completion":993,"start":994,"enrollment":995,"conditions":996,"interventions":998},"NCT01460225","Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation",[92],"2010-12","2011-01","2007-09",19,[997],"Chronic Idiopathic Constipation",[976],{"trials":1000,"activeCount":100},[],{"intervention":1002,"totalTrials":96,"cells":1003},"Lidocaine topical",{"EARLY_PHASE1":1004,"PHASE1":1006,"PHASE2":1008,"PHASE3":1010,"PHASE4":1012,"NA":1025},{"trials":1005,"activeCount":100},[],{"trials":1007,"activeCount":100},[],{"trials":1009,"activeCount":100},[],{"trials":1011,"activeCount":100},[],{"trials":1013,"activeCount":100},[1014],{"nctId":1015,"briefTitle":1016,"status":186,"phases":1017,"primaryCompletion":1018,"completion":1018,"start":1019,"enrollment":1020,"conditions":1021,"interventions":1023},"NCT06569537","Comparison of Compounded Topical Anesthetics",[92],"2025-12-19","2024-10-22",63,[1022],"Procedural Pain",[1002,1024],"BLT",{"trials":1026,"activeCount":100},[],{"intervention":1024,"totalTrials":96,"cells":1028},{"EARLY_PHASE1":1029,"PHASE1":1031,"PHASE2":1033,"PHASE3":1035,"PHASE4":1037,"NA":1043},{"trials":1030,"activeCount":100},[],{"trials":1032,"activeCount":100},[],{"trials":1034,"activeCount":100},[],{"trials":1036,"activeCount":100},[],{"trials":1038,"activeCount":100},[1039],{"nctId":1015,"briefTitle":1016,"status":186,"phases":1040,"primaryCompletion":1018,"completion":1018,"start":1019,"enrollment":1020,"conditions":1041,"interventions":1042},[92],[1022],[1002,1024],{"trials":1044,"activeCount":100},[],{"intervention":1046,"totalTrials":96,"cells":1047},"Treatment as usual",{"EARLY_PHASE1":1048,"PHASE1":1050,"PHASE2":1052,"PHASE3":1054,"PHASE4":1056,"NA":1069},{"trials":1049,"activeCount":100},[],{"trials":1051,"activeCount":100},[],{"trials":1053,"activeCount":100},[],{"trials":1055,"activeCount":100},[],{"trials":1057,"activeCount":100},[1058],{"nctId":1059,"briefTitle":1060,"status":186,"phases":1061,"primaryCompletion":376,"completion":376,"start":1062,"enrollment":1063,"conditions":1064,"interventions":1067},"NCT00498550","Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual",[92],"2000-10",31,[15,1065,21,945,1066],"Dual Diagnosis","Cannabis Abuse",[1068,1046],"Clozapine",{"trials":1070,"activeCount":100},[],{"intervention":1072,"totalTrials":96,"cells":1073},"Arformoterol tartrate",{"EARLY_PHASE1":1074,"PHASE1":1076,"PHASE2":1078,"PHASE3":1080,"PHASE4":1082,"NA":1092},{"trials":1075,"activeCount":100},[],{"trials":1077,"activeCount":100},[],{"trials":1079,"activeCount":100},[],{"trials":1081,"activeCount":100},[],{"trials":1083,"activeCount":100},[1084],{"nctId":1085,"briefTitle":1086,"status":186,"phases":1087,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":276,"conditions":1090,"interventions":1091},"NCT00754546","Effect of Bronchodilation on Cycle vs Treadmill Exercise Endurance Time in COPD",[92],"2009-05","2008-08",[192],[1072],{"trials":1093,"activeCount":100},[],{"intervention":1095,"totalTrials":96,"cells":1096},"S-Adenosyl-L-Methionine",{"EARLY_PHASE1":1097,"PHASE1":1099,"PHASE2":1101,"PHASE3":1103,"PHASE4":1105,"NA":1117},{"trials":1098,"activeCount":100},[],{"trials":1100,"activeCount":100},[],{"trials":1102,"activeCount":100},[],{"trials":1104,"activeCount":100},[],{"trials":1106,"activeCount":100},[1107],{"nctId":1108,"briefTitle":1109,"status":186,"phases":1110,"primaryCompletion":1111,"completion":1111,"start":1112,"enrollment":1113,"conditions":1114,"interventions":1116},"NCT05363020","S-Asenosyl-L-Methionine vs Placebo for Osteoarthritis of the Hands",[92],"2025-04-11","2022-08-17",40,[1115],"Osteoarthritis Hand",[1095],{"trials":1118,"activeCount":100},[],{"intervention":1120,"totalTrials":96,"cells":1121},"Enteric Coated Aspirin",{"EARLY_PHASE1":1122,"PHASE1":1124,"PHASE2":1126,"PHASE3":1128,"PHASE4":1130,"NA":1145},{"trials":1123,"activeCount":100},[],{"trials":1125,"activeCount":100},[],{"trials":1127,"activeCount":100},[],{"trials":1129,"activeCount":100},[],{"trials":1131,"activeCount":100},[1132],{"nctId":1133,"briefTitle":1134,"status":186,"phases":1135,"primaryCompletion":1136,"completion":1136,"start":1137,"enrollment":1138,"conditions":1139,"interventions":1142},"NCT02810704","Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement",[92],"2025-09","2016-12",18883,[1140,1141],"Pulmonary Embolism","Venous Thrombosis",[1120,1143,1144],"Warfarin","Rivaroxaban",{"trials":1146,"activeCount":100},[],{"intervention":1143,"totalTrials":96,"cells":1148},{"EARLY_PHASE1":1149,"PHASE1":1151,"PHASE2":1153,"PHASE3":1155,"PHASE4":1157,"NA":1163},{"trials":1150,"activeCount":100},[],{"trials":1152,"activeCount":100},[],{"trials":1154,"activeCount":100},[],{"trials":1156,"activeCount":100},[],{"trials":1158,"activeCount":100},[1159],{"nctId":1133,"briefTitle":1134,"status":186,"phases":1160,"primaryCompletion":1136,"completion":1136,"start":1137,"enrollment":1138,"conditions":1161,"interventions":1162},[92],[1140,1141],[1120,1143,1144],{"trials":1164,"activeCount":100},[],{"intervention":1144,"totalTrials":96,"cells":1166},{"EARLY_PHASE1":1167,"PHASE1":1169,"PHASE2":1171,"PHASE3":1173,"PHASE4":1175,"NA":1181},{"trials":1168,"activeCount":100},[],{"trials":1170,"activeCount":100},[],{"trials":1172,"activeCount":100},[],{"trials":1174,"activeCount":100},[],{"trials":1176,"activeCount":100},[1177],{"nctId":1133,"briefTitle":1134,"status":186,"phases":1178,"primaryCompletion":1136,"completion":1136,"start":1137,"enrollment":1138,"conditions":1179,"interventions":1180},[92],[1140,1141],[1120,1143,1144],{"trials":1182,"activeCount":100},[],{"intervention":1184,"totalTrials":96,"cells":1185},"darbepoetin alfa",{"EARLY_PHASE1":1186,"PHASE1":1188,"PHASE2":1190,"PHASE3":1192,"PHASE4":1194,"NA":1206},{"trials":1187,"activeCount":100},[],{"trials":1189,"activeCount":100},[],{"trials":1191,"activeCount":100},[],{"trials":1193,"activeCount":100},[],{"trials":1195,"activeCount":100},[1196],{"nctId":1197,"briefTitle":1198,"status":186,"phases":1199,"primaryCompletion":1200,"completion":1200,"start":1201,"enrollment":1202,"conditions":1203,"interventions":1205},"NCT00153868","A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer",[92],"2007-08-17","2003-10",43,[1204,34],"Anemia",[1184],{"trials":1207,"activeCount":100},[],{"intervention":1209,"totalTrials":96,"cells":1210},"Risperidone Long Acting",{"EARLY_PHASE1":1211,"PHASE1":1213,"PHASE2":1215,"PHASE3":1217,"PHASE4":1219,"NA":1232},{"trials":1212,"activeCount":100},[],{"trials":1214,"activeCount":100},[],{"trials":1216,"activeCount":100},[],{"trials":1218,"activeCount":100},[],{"trials":1220,"activeCount":100},[1221],{"nctId":1222,"briefTitle":1223,"status":186,"phases":1224,"primaryCompletion":1225,"completion":1226,"start":404,"enrollment":1227,"conditions":1228,"interventions":1230},"NCT00130923","Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder",[92],"2009-06","2010-07",95,[15,1229,946,947],"Psychotic Disorders",[1209,1231],"oral risperidone",{"trials":1233,"activeCount":100},[],{"intervention":1231,"totalTrials":96,"cells":1235},{"EARLY_PHASE1":1236,"PHASE1":1238,"PHASE2":1240,"PHASE3":1242,"PHASE4":1244,"NA":1250},{"trials":1237,"activeCount":100},[],{"trials":1239,"activeCount":100},[],{"trials":1241,"activeCount":100},[],{"trials":1243,"activeCount":100},[],{"trials":1245,"activeCount":100},[1246],{"nctId":1222,"briefTitle":1223,"status":186,"phases":1247,"primaryCompletion":1225,"completion":1226,"start":404,"enrollment":1227,"conditions":1248,"interventions":1249},[92],[15,1229,946,947],[1209,1231],{"trials":1251,"activeCount":100},[],{"intervention":1253,"totalTrials":96,"cells":1254},"Genetically Informed Therapy",{"EARLY_PHASE1":1255,"PHASE1":1257,"PHASE2":1259,"PHASE3":1261,"PHASE4":1263,"NA":1274},{"trials":1256,"activeCount":100},[],{"trials":1258,"activeCount":100},[],{"trials":1260,"activeCount":100},[],{"trials":1262,"activeCount":100},[],{"trials":1264,"activeCount":100},[1265],{"nctId":1266,"briefTitle":1267,"status":160,"phases":1268,"primaryCompletion":1269,"completion":1269,"start":1270,"enrollment":100,"conditions":1271,"interventions":1273},"NCT02000739","Genetically-informed Therapies for Patients With Metastatic Cancer",[92],"2018-01","2014-01",[1272],"Metastatic Cancer",[1253],{"trials":1275,"activeCount":100},[],{"intervention":1277,"totalTrials":96,"cells":1278},"ketoconazole",{"EARLY_PHASE1":1279,"PHASE1":1281,"PHASE2":1283,"PHASE3":1285,"PHASE4":1287,"NA":1298},{"trials":1280,"activeCount":100},[],{"trials":1282,"activeCount":100},[],{"trials":1284,"activeCount":100},[],{"trials":1286,"activeCount":100},[],{"trials":1288,"activeCount":100},[1289],{"nctId":1290,"briefTitle":1291,"status":186,"phases":1292,"primaryCompletion":1293,"completion":1293,"start":1294,"enrollment":276,"conditions":1295,"interventions":1296},"NCT01378520","Effect of Ketoconazole on Breathlessness",[92],"2012-02","2011-06",[192],[1277,1297],"inert powder",{"trials":1299,"activeCount":100},[],{"intervention":1297,"totalTrials":96,"cells":1301},{"EARLY_PHASE1":1302,"PHASE1":1304,"PHASE2":1306,"PHASE3":1308,"PHASE4":1310,"NA":1316},{"trials":1303,"activeCount":100},[],{"trials":1305,"activeCount":100},[],{"trials":1307,"activeCount":100},[],{"trials":1309,"activeCount":100},[],{"trials":1311,"activeCount":100},[1312],{"nctId":1290,"briefTitle":1291,"status":186,"phases":1313,"primaryCompletion":1293,"completion":1293,"start":1294,"enrollment":276,"conditions":1314,"interventions":1315},[92],[192],[1277,1297],{"trials":1317,"activeCount":100},[],{"intervention":1319,"totalTrials":96,"cells":1320},"Clozapine versus typical (conventional) and atypical antipsychotic medications",{"EARLY_PHASE1":1321,"PHASE1":1323,"PHASE2":1325,"PHASE3":1327,"PHASE4":1329,"NA":1340},{"trials":1322,"activeCount":100},[],{"trials":1324,"activeCount":100},[],{"trials":1326,"activeCount":100},[],{"trials":1328,"activeCount":100},[],{"trials":1330,"activeCount":100},[1331],{"nctId":1332,"briefTitle":1333,"status":287,"phases":1334,"completion":1335,"start":1336,"enrollment":1337,"conditions":1338,"interventions":1339},"NCT00169026","Alcoholism and Schizophrenia: Effects of Clozapine",[92],"2004-01","1999-05",64,[15,1065,21,945,946,947],[1319],{"trials":1341,"activeCount":100},[],{"intervention":382,"totalTrials":444,"cells":1343},{"EARLY_PHASE1":1344,"PHASE1":1346,"PHASE2":1357,"PHASE3":1359,"PHASE4":1365,"NA":1367},{"trials":1345,"activeCount":100},[],{"trials":1347,"activeCount":100},[1348],{"nctId":1349,"briefTitle":1350,"status":186,"phases":1351,"primaryCompletion":1352,"start":1353,"enrollment":29,"conditions":1354,"interventions":1355},"NCT00014430","Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer",[89],"2002-09","1999-11",[18],[382,1356],"vinorelbine ditartrate",{"trials":1358,"activeCount":100},[],{"trials":1360,"activeCount":100},[1361],{"nctId":373,"briefTitle":374,"status":287,"phases":1362,"primaryCompletion":376,"completion":376,"start":377,"enrollment":378,"conditions":1363,"interventions":1364},[90,91],[380],[316,382,383,316,384],{"trials":1366,"activeCount":100},[],{"trials":1368,"activeCount":100},[],{"intervention":1370,"totalTrials":96,"cells":1371},"Indomethacin",{"EARLY_PHASE1":1372,"PHASE1":1374,"PHASE2":1376,"PHASE3":1378,"PHASE4":1389,"NA":1391},{"trials":1373,"activeCount":100},[],{"trials":1375,"activeCount":100},[],{"trials":1377,"activeCount":100},[],{"trials":1379,"activeCount":100},[1380],{"nctId":1381,"briefTitle":1382,"status":287,"phases":1383,"primaryCompletion":1384,"completion":1384,"start":289,"enrollment":1385,"conditions":1386,"interventions":1388},"NCT01774604","Rectal Indomethacin to Prevent Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis",[91],"2014-12",449,[1387],"Post-ERCP Acute Pancreatitis",[1370],{"trials":1390,"activeCount":100},[],{"trials":1392,"activeCount":100},[],{"intervention":1394,"totalTrials":96,"cells":1395},"Aspirin",{"EARLY_PHASE1":1396,"PHASE1":1398,"PHASE2":1400,"PHASE3":1402,"PHASE4":1417,"NA":1419},{"trials":1397,"activeCount":100},[],{"trials":1399,"activeCount":100},[],{"trials":1401,"activeCount":100},[],{"trials":1403,"activeCount":100},[1404],{"nctId":1405,"briefTitle":1406,"status":186,"phases":1407,"completion":1408,"start":1409,"enrollment":1410,"conditions":1411,"interventions":1415},"NCT00272324","Aspirin\u002FFolate Prevention of Large Bowel Polyps",[90,91],"2007-01","1992-02",1121,[1412,1413,1414],"Colorectal Cancer","Polyps","Adenomas",[1394,1416],"Folate",{"trials":1418,"activeCount":100},[],{"trials":1420,"activeCount":100},[],{"intervention":1416,"totalTrials":96,"cells":1422},{"EARLY_PHASE1":1423,"PHASE1":1425,"PHASE2":1427,"PHASE3":1429,"PHASE4":1435,"NA":1437},{"trials":1424,"activeCount":100},[],{"trials":1426,"activeCount":100},[],{"trials":1428,"activeCount":100},[],{"trials":1430,"activeCount":100},[1431],{"nctId":1405,"briefTitle":1406,"status":186,"phases":1432,"completion":1408,"start":1409,"enrollment":1410,"conditions":1433,"interventions":1434},[90,91],[1412,1413,1414],[1394,1416],{"trials":1436,"activeCount":100},[],{"trials":1438,"activeCount":100},[],{"intervention":1440,"totalTrials":96,"cells":1441},"Extract of Green and Black Tea",{"EARLY_PHASE1":1442,"PHASE1":1444,"PHASE2":1446,"PHASE3":1448,"PHASE4":1460,"NA":1462},{"trials":1443,"activeCount":100},[],{"trials":1445,"activeCount":100},[],{"trials":1447,"activeCount":100},[],{"trials":1449,"activeCount":100},[1450],{"nctId":1451,"briefTitle":1452,"status":186,"phases":1453,"completion":1454,"start":1455,"enrollment":1456,"conditions":1457,"interventions":1459},"NCT00389350","Effect of an Extract of Green Tea on Adults With Type 2 Diabetes",[90,91],"2006-06","2005-08",48,[1458],"Diabetes",[1440],{"trials":1461,"activeCount":100},[],{"trials":1463,"activeCount":100},[],{"intervention":1465,"totalTrials":96,"cells":1466},"cinnamon",{"EARLY_PHASE1":1467,"PHASE1":1469,"PHASE2":1471,"PHASE3":1473,"PHASE4":1485,"NA":1487},{"trials":1468,"activeCount":100},[],{"trials":1470,"activeCount":100},[],{"trials":1472,"activeCount":100},[],{"trials":1474,"activeCount":100},[1475],{"nctId":1476,"briefTitle":1477,"status":186,"phases":1478,"completion":1479,"start":1480,"enrollment":1481,"conditions":1482,"interventions":1484},"NCT00371800","The Effect of Cinnamon on HbA1c Among Adolescents With Type I Diabetes",[90,91],"2006-05","2005-10",72,[1483],"Type 1 Diabetes Mellitus",[1465],{"trials":1486,"activeCount":100},[],{"trials":1488,"activeCount":100},[],{"intervention":1490,"totalTrials":96,"cells":1491},"Calcium Carbonate",{"EARLY_PHASE1":1492,"PHASE1":1494,"PHASE2":1496,"PHASE3":1498,"PHASE4":1511,"NA":1513},{"trials":1493,"activeCount":100},[],{"trials":1495,"activeCount":100},[],{"trials":1497,"activeCount":100},[],{"trials":1499,"activeCount":100},[1500],{"nctId":1501,"briefTitle":1502,"status":186,"phases":1503,"primaryCompletion":1504,"completion":1505,"start":1506,"enrollment":1507,"conditions":1508,"interventions":1509},"NCT00153816","Vitamin D\u002FCalcium Polyp Prevention Study",[90,91],"2013-10","2016-06","2004-07",2813,[1412,1413,1414],[1490,1510],"Vitamin D3",{"trials":1512,"activeCount":100},[],{"trials":1514,"activeCount":100},[],{"intervention":1510,"totalTrials":96,"cells":1516},{"EARLY_PHASE1":1517,"PHASE1":1519,"PHASE2":1521,"PHASE3":1523,"PHASE4":1529,"NA":1531},{"trials":1518,"activeCount":100},[],{"trials":1520,"activeCount":100},[],{"trials":1522,"activeCount":100},[],{"trials":1524,"activeCount":100},[1525],{"nctId":1501,"briefTitle":1502,"status":186,"phases":1526,"primaryCompletion":1504,"completion":1505,"start":1506,"enrollment":1507,"conditions":1527,"interventions":1528},[90,91],[1412,1413,1414],[1490,1510],{"trials":1530,"activeCount":100},[],{"trials":1532,"activeCount":100},[],{"intervention":1534,"totalTrials":96,"cells":1535},"Secretin",{"EARLY_PHASE1":1536,"PHASE1":1538,"PHASE2":1540,"PHASE3":1542,"PHASE4":1554,"NA":1556},{"trials":1537,"activeCount":100},[],{"trials":1539,"activeCount":100},[],{"trials":1541,"activeCount":100},[],{"trials":1543,"activeCount":100},[1544],{"nctId":1545,"briefTitle":1546,"status":186,"phases":1547,"primaryCompletion":1548,"completion":1548,"start":1549,"enrollment":1550,"conditions":1551,"interventions":1553},"NCT02160808","Secretin Infusion to Prevent Pancreatic Leaks Following Pancreatic Resection",[90,91],"2019-09-21","2014-05",170,[1552],"Injury of Body of Pancreas",[1534],{"trials":1555,"activeCount":100},[],{"trials":1557,"activeCount":100},[],{"intervention":383,"totalTrials":96,"cells":1559},{"EARLY_PHASE1":1560,"PHASE1":1562,"PHASE2":1564,"PHASE3":1566,"PHASE4":1572,"NA":1574},{"trials":1561,"activeCount":100},[],{"trials":1563,"activeCount":100},[],{"trials":1565,"activeCount":100},[],{"trials":1567,"activeCount":100},[1568],{"nctId":373,"briefTitle":374,"status":287,"phases":1569,"primaryCompletion":376,"completion":376,"start":377,"enrollment":378,"conditions":1570,"interventions":1571},[90,91],[380],[316,382,383,316,384],{"trials":1573,"activeCount":100},[],{"trials":1575,"activeCount":100},[],{"intervention":384,"totalTrials":96,"cells":1577},{"EARLY_PHASE1":1578,"PHASE1":1580,"PHASE2":1582,"PHASE3":1584,"PHASE4":1590,"NA":1592},{"trials":1579,"activeCount":100},[],{"trials":1581,"activeCount":100},[],{"trials":1583,"activeCount":100},[],{"trials":1585,"activeCount":100},[1586],{"nctId":373,"briefTitle":374,"status":287,"phases":1587,"primaryCompletion":376,"completion":376,"start":377,"enrollment":378,"conditions":1588,"interventions":1589},[90,91],[380],[316,382,383,316,384],{"trials":1591,"activeCount":100},[],{"trials":1593,"activeCount":100},[],{"intervention":1595,"totalTrials":96,"cells":1596},"SRL-172",{"EARLY_PHASE1":1597,"PHASE1":1599,"PHASE2":1601,"PHASE3":1603,"PHASE4":1615,"NA":1617},{"trials":1598,"activeCount":100},[],{"trials":1600,"activeCount":100},[],{"trials":1602,"activeCount":100},[],{"trials":1604,"activeCount":100},[1605],{"nctId":1606,"briefTitle":1607,"status":186,"phases":1608,"primaryCompletion":273,"completion":1088,"start":1609,"enrollment":1610,"conditions":1611,"interventions":1614},"NCT00052195","Investigational Vaccine for the Prevention of Disseminated Tuberculosis in HIV Infected People",[90,91],"2001-09",1975,[1612,1613],"Tuberculosis","HIV Infections",[1595],{"trials":1616,"activeCount":100},[],{"trials":1618,"activeCount":100},[],{"intervention":1620,"totalTrials":149,"cells":1621},"temozolomide",{"EARLY_PHASE1":1622,"PHASE1":1624,"PHASE2":1635,"PHASE3":1660,"PHASE4":1662,"NA":1664},{"trials":1623,"activeCount":100},[],{"trials":1625,"activeCount":100},[1626],{"nctId":1627,"briefTitle":1628,"status":186,"phases":1629,"primaryCompletion":1630,"completion":1630,"start":1062,"conditions":1631,"interventions":1633},"NCT00014261","Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors",[89],"2002-11",[1632],"Unspecified Adult Solid Tumor, Protocol Specific",[1634,1620],"PEG-interferon alfa-2b",{"trials":1636,"activeCount":100},[1637,1648],{"nctId":1638,"briefTitle":1639,"status":287,"phases":1640,"primaryCompletion":1641,"completion":1641,"start":1642,"enrollment":32,"conditions":1643,"interventions":1647},"NCT00005812","Temozolomide in Treating Patients With Leptomeningeal Metastases From a Solid Tumor or Lymphoma",[90],"2004-05","2000-01",[1644,1645,1646],"Brain Tumors","Central Nervous System Tumors","Leptomeningeal Metastases",[1620],{"nctId":1649,"briefTitle":1650,"status":186,"phases":1651,"primaryCompletion":1652,"completion":1653,"start":1479,"enrollment":35,"conditions":1654,"interventions":1656},"NCT00323115","Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme",[90],"2008-04","2013-07",[1655],"Glioblastoma Multiforme",[1657,1658,1659],"Autologous Dendritic Cell","Temozolomide","Dendritic Cell Vaccine",{"trials":1661,"activeCount":100},[],{"trials":1663,"activeCount":100},[],{"trials":1665,"activeCount":100},[],{"intervention":1667,"totalTrials":149,"cells":1668},"Rituximab",{"EARLY_PHASE1":1669,"PHASE1":1671,"PHASE2":1685,"PHASE3":1707,"PHASE4":1709,"NA":1711},{"trials":1670,"activeCount":100},[],{"trials":1672,"activeCount":100},[1673],{"nctId":1674,"briefTitle":1675,"status":186,"phases":1676,"primaryCompletion":1677,"completion":1678,"start":1679,"enrollment":1680,"conditions":1681,"interventions":1683},"NCT01832922","BR in Patients With CLL With Comorbidities and\u002For Renal Dysfunction",[89],"2015-04-27","2016-11-28","2013-04",8,[215,1682],"Small Lymphocytic Lymphoma",[1684,1667],"Bendamustine",{"trials":1686,"activeCount":100},[1687,1697],{"nctId":1688,"briefTitle":1689,"status":287,"phases":1690,"primaryCompletion":1691,"completion":1691,"start":1692,"enrollment":444,"conditions":1693,"interventions":1695},"NCT03689894","Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT",[89,90],"2021-09-20","2019-04-11",[1694],"Chronic Graft-versus-host-disease",[1696,1667],"Ibrutinib",{"nctId":1698,"briefTitle":1699,"status":186,"phases":1700,"primaryCompletion":1701,"completion":1702,"start":189,"enrollment":1703,"conditions":1704,"interventions":1706},"NCT01234766","Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma",[90],"2021-01","2021-04-01",39,[1705],"Lymphoma, Follicular",[1684,1667],{"trials":1708,"activeCount":100},[],{"trials":1710,"activeCount":100},[],{"trials":1712,"activeCount":100},[],{"intervention":281,"totalTrials":149,"cells":1714},{"EARLY_PHASE1":1715,"PHASE1":1717,"PHASE2":1739,"PHASE3":1745,"PHASE4":1747,"NA":1749},{"trials":1716,"activeCount":100},[],{"trials":1718,"activeCount":100},[1719,1730],{"nctId":1720,"briefTitle":1721,"status":186,"phases":1722,"primaryCompletion":1723,"completion":1723,"start":1724,"enrollment":11,"conditions":1725,"interventions":1727},"NCT00003003","Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia",[89],"2000-08","1996-09",[1726],"Leukemia",[281,1728,1729],"mitomycin C","mitoxantrone hydrochloride",{"nctId":1731,"briefTitle":1732,"status":287,"phases":1733,"primaryCompletion":1734,"completion":1734,"start":1735,"enrollment":149,"conditions":1736,"interventions":1737},"NCT00014560","Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",[89],"2003-02-14","2000-09-28",[1726,220],[1738,281],"bispecific antibody 4G7xH22",{"trials":1740,"activeCount":100},[1741],{"nctId":270,"briefTitle":271,"status":186,"phases":1742,"primaryCompletion":273,"completion":274,"start":275,"enrollment":276,"conditions":1743,"interventions":1744},[90],[278],[280,281,282,283],{"trials":1746,"activeCount":100},[],{"trials":1748,"activeCount":100},[],{"trials":1750,"activeCount":100},[],{"intervention":1752,"totalTrials":149,"cells":1753},"Bevacizumab",{"EARLY_PHASE1":1754,"PHASE1":1764,"PHASE2":1766,"PHASE3":1788,"PHASE4":1790,"NA":1792},{"trials":1755,"activeCount":100},[1756],{"nctId":1757,"briefTitle":1758,"status":186,"phases":1759,"primaryCompletion":1760,"completion":1760,"start":1761,"enrollment":29,"conditions":1762,"interventions":1763},"NCT01091792","Exploratory Study of the Modulation of the Immune System by VEGF Blockade in Patients With Glioblastoma Multiforme (GBM)",[88],"2015-04-02","2010-03",[1655],[1752],{"trials":1765,"activeCount":100},[],{"trials":1767,"activeCount":100},[1768,1779],{"nctId":1769,"briefTitle":1770,"status":287,"phases":1771,"primaryCompletion":289,"completion":289,"start":1772,"enrollment":1680,"conditions":1773,"interventions":1775},"NCT00913913","Bevacizumab, Autologous Tumor\u002FDC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients",[90],"2009-02",[1774],"Metastatic Renal Cell Carcinoma",[1776,1752,1777,1778],"DC vaccine","IL-2","IFN",{"nctId":1780,"briefTitle":1781,"status":160,"phases":1782,"completion":1783,"start":1784,"enrollment":100,"conditions":1785,"interventions":1787},"NCT00469469","Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma",[90],"2009-09","2007-05",[1786],"Adrenocortical Carcinoma",[1752],{"trials":1789,"activeCount":100},[],{"trials":1791,"activeCount":100},[],{"trials":1793,"activeCount":100},[],{"intervention":1795,"totalTrials":444,"cells":1796},"thalidomide",{"EARLY_PHASE1":1797,"PHASE1":1799,"PHASE2":1801,"PHASE3":1824,"PHASE4":1826,"NA":1828},{"trials":1798,"activeCount":100},[],{"trials":1800,"activeCount":100},[],{"trials":1802,"activeCount":100},[1803,1813],{"nctId":1804,"briefTitle":1805,"status":186,"phases":1806,"primaryCompletion":994,"completion":1807,"start":1808,"enrollment":19,"conditions":1809,"interventions":1811},"NCT00039468","Thalidomide and Irinotecan in Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation Therapy",[90],"2008-02","2002-03",[1810],"Brain and Central Nervous System Tumors",[1812,1795],"irinotecan hydrochloride",{"nctId":1814,"briefTitle":1815,"status":186,"phases":1816,"completion":1817,"start":1818,"enrollment":810,"conditions":1819,"interventions":1822},"NCT00140452","Phase II Study Using Thalidomide for the Treatment of ALS",[90],"2007-11","2005-02",[1820,1821],"Amyotrophic Lateral Sclerosis","ALS",[1823],"Thalidomide",{"trials":1825,"activeCount":100},[],{"trials":1827,"activeCount":100},[],{"trials":1829,"activeCount":100},[],{"intervention":1831,"totalTrials":444,"cells":1832},"filgrastim",{"EARLY_PHASE1":1833,"PHASE1":1835,"PHASE2":1855,"PHASE3":1868,"PHASE4":1870,"NA":1872},{"trials":1834,"activeCount":100},[],{"trials":1836,"activeCount":100},[1837],{"nctId":1838,"briefTitle":1839,"status":186,"phases":1840,"primaryCompletion":1480,"completion":1480,"start":1841,"enrollment":658,"conditions":1842,"interventions":1852},"NCT00014456","Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors",[89],"2000-03",[1843,18,1844,1845,1846,790,1847,278,1848,1849,1850,1851],"Bladder Cancer","Carcinoma of Unknown Primary","Esophageal Cancer","Gastric Cancer","Lung Cancer","Ovarian Cancer","Pancreatic Cancer","Prostate Cancer","Sarcoma",[1831,1853,1854],"docetaxel","gemcitabine hydrochloride",{"trials":1856,"activeCount":100},[1857],{"nctId":1858,"briefTitle":1859,"status":186,"phases":1860,"primaryCompletion":1861,"completion":1862,"start":1863,"enrollment":276,"conditions":1864,"interventions":1865},"NCT00002814","Combination Chemotherapy for Patients With Brain Cancer",[90],"2001-04","2001-12","1996-08",[1810],[1831,1866,1867],"paclitaxel","topotecan hydrochloride",{"trials":1869,"activeCount":100},[],{"trials":1871,"activeCount":100},[],{"trials":1873,"activeCount":100},[],{"intervention":1875,"totalTrials":444,"cells":1876},"DAR-901",{"EARLY_PHASE1":1877,"PHASE1":1879,"PHASE2":1892,"PHASE3":1903,"PHASE4":1905,"NA":1907},{"trials":1878,"activeCount":100},[],{"trials":1880,"activeCount":100},[1881],{"nctId":1882,"briefTitle":1883,"status":186,"phases":1884,"primaryCompletion":1885,"completion":1505,"start":1886,"enrollment":1887,"conditions":1888,"interventions":1889},"NCT02063555","Phase I Trial of DAR-901",[89],"2016-03","2014-02",59,[1612],[1875,1890,1891],"BCG","Sterile saline",{"trials":1893,"activeCount":100},[1894],{"nctId":1895,"briefTitle":1896,"status":186,"phases":1897,"primaryCompletion":1898,"completion":1898,"start":1885,"enrollment":1899,"conditions":1900,"interventions":1901},"NCT02712424","DAR-901 TB Booster Vaccine to Prevent TB in Adolescents",[90],"2020-02-01",625,[1612],[1875,1902],"Sterile saline placebo",{"trials":1904,"activeCount":100},[],{"trials":1906,"activeCount":100},[],{"trials":1908,"activeCount":100},[],{"intervention":1696,"totalTrials":444,"cells":1910},{"EARLY_PHASE1":1911,"PHASE1":1913,"PHASE2":1925,"PHASE3":1931,"PHASE4":1933,"NA":1935},{"trials":1912,"activeCount":100},[],{"trials":1914,"activeCount":100},[1915],{"nctId":1916,"briefTitle":1917,"status":186,"phases":1918,"primaryCompletion":1919,"completion":1919,"start":1920,"enrollment":1921,"conditions":1922,"interventions":1923},"NCT03454165","A Study of BNC105P Combined With Ibrutinib",[89],"2021-01-14","2018-03-09",6,[215],[1924,1696],"BNC105P",{"trials":1926,"activeCount":100},[1927],{"nctId":1688,"briefTitle":1689,"status":287,"phases":1928,"primaryCompletion":1691,"completion":1691,"start":1692,"enrollment":444,"conditions":1929,"interventions":1930},[89,90],[1694],[1696,1667],{"trials":1932,"activeCount":100},[],{"trials":1934,"activeCount":100},[],{"trials":1936,"activeCount":100},[],{"intervention":1938,"totalTrials":444,"cells":1939},"autologous tumor cell vaccine",{"EARLY_PHASE1":1940,"PHASE1":1942,"PHASE2":1952,"PHASE3":1965,"PHASE4":1967,"NA":1969},{"trials":1941,"activeCount":100},[],{"trials":1943,"activeCount":100},[1944],{"nctId":1945,"briefTitle":1946,"status":186,"phases":1947,"primaryCompletion":1948,"completion":1948,"start":275,"conditions":1949,"interventions":1950},"NCT00085488","Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma",[89],"2006-02",[278],[1938,1951],"therapeutic autologous dendritic cells",{"trials":1953,"activeCount":100},[1954],{"nctId":1955,"briefTitle":1956,"status":186,"phases":1957,"primaryCompletion":1958,"completion":1958,"start":1959,"enrollment":313,"conditions":1960,"interventions":1962},"NCT00085436","DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC",[90],"2009-10","2003-12",[1961],"Kidney Cancer",[1963,1938,1964],"Aldesleukin,","recombinant interferon alfa",{"trials":1966,"activeCount":100},[],{"trials":1968,"activeCount":100},[],{"trials":1970,"activeCount":100},[],{"intervention":1972,"totalTrials":444,"cells":1973},"Bexarotene",{"EARLY_PHASE1":1974,"PHASE1":1976,"PHASE2":1988,"PHASE3":1998,"PHASE4":2000,"NA":2002},{"trials":1975,"activeCount":100},[],{"trials":1977,"activeCount":100},[1978],{"nctId":1979,"briefTitle":1980,"status":186,"phases":1981,"primaryCompletion":1982,"completion":1982,"start":1983,"enrollment":810,"conditions":1984,"interventions":1986},"NCT01116622","Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract",[89],"2014-04","2003-04",[1985],"Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus)",[1972,1987],"Erlotinib",{"trials":1989,"activeCount":100},[1990],{"nctId":1991,"briefTitle":1992,"status":287,"phases":1993,"primaryCompletion":376,"completion":376,"start":1994,"enrollment":821,"conditions":1995,"interventions":1997},"NCT00153842","A Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules in Patients With Advanced Lung Cancer",[89,90],"2001-08",[1996],"Carcinoma, Non-small-cell Lung",[1972,1972],{"trials":1999,"activeCount":100},[],{"trials":2001,"activeCount":100},[],{"trials":2003,"activeCount":100},[],{"intervention":1777,"totalTrials":444,"cells":2005},{"EARLY_PHASE1":2006,"PHASE1":2008,"PHASE2":2021,"PHASE3":2027,"PHASE4":2029,"NA":2031},{"trials":2007,"activeCount":100},[],{"trials":2009,"activeCount":100},[2010],{"nctId":2011,"briefTitle":2012,"status":186,"phases":2013,"primaryCompletion":2014,"completion":2014,"start":406,"enrollment":29,"conditions":2015,"interventions":2019},"NCT00952237","Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF",[89],"2011-04",[2016,2017,337,2018,1726],"Non-Hodgkin's Lymphoma","Hodgkin's Disease","Other Plasma Cell Dyscrasia (Waldenstrom, Amyloidosis)",[2020,1777],"GM-CSF",{"trials":2022,"activeCount":100},[2023],{"nctId":1769,"briefTitle":1770,"status":287,"phases":2024,"primaryCompletion":289,"completion":289,"start":1772,"enrollment":1680,"conditions":2025,"interventions":2026},[90],[1774],[1776,1752,1777,1778],{"trials":2028,"activeCount":100},[],{"trials":2030,"activeCount":100},[],{"trials":2032,"activeCount":100},[],{"intervention":1684,"totalTrials":444,"cells":2034},{"EARLY_PHASE1":2035,"PHASE1":2037,"PHASE2":2043,"PHASE3":2049,"PHASE4":2051,"NA":2053},{"trials":2036,"activeCount":100},[],{"trials":2038,"activeCount":100},[2039],{"nctId":1674,"briefTitle":1675,"status":186,"phases":2040,"primaryCompletion":1677,"completion":1678,"start":1679,"enrollment":1680,"conditions":2041,"interventions":2042},[89],[215,1682],[1684,1667],{"trials":2044,"activeCount":100},[2045],{"nctId":1698,"briefTitle":1699,"status":186,"phases":2046,"primaryCompletion":1701,"completion":1702,"start":189,"enrollment":1703,"conditions":2047,"interventions":2048},[90],[1705],[1684,1667],{"trials":2050,"activeCount":100},[],{"trials":2052,"activeCount":100},[],{"trials":2054,"activeCount":100},[],{"intervention":2056,"totalTrials":96,"cells":2057},"Sunitinib",{"EARLY_PHASE1":2058,"PHASE1":2060,"PHASE2":2062,"PHASE3":2074,"PHASE4":2076,"NA":2078},{"trials":2059,"activeCount":100},[],{"trials":2061,"activeCount":100},[],{"trials":2063,"activeCount":100},[2064],{"nctId":2065,"briefTitle":2066,"status":186,"phases":2067,"primaryCompletion":2068,"completion":2068,"start":2069,"enrollment":2070,"conditions":2071,"interventions":2072},"NCT01517243","Phase II Study of Alternating Sunitinib and Temsirolimus",[90],"2018-08-20","2010-09-22",37,[1774],[2056,2073],"Temsirolimus",{"trials":2075,"activeCount":100},[],{"trials":2077,"activeCount":100},[],{"trials":2079,"activeCount":100},[],{"intervention":2073,"totalTrials":96,"cells":2081},{"EARLY_PHASE1":2082,"PHASE1":2084,"PHASE2":2086,"PHASE3":2092,"PHASE4":2094,"NA":2096},{"trials":2083,"activeCount":100},[],{"trials":2085,"activeCount":100},[],{"trials":2087,"activeCount":100},[2088],{"nctId":2065,"briefTitle":2066,"status":186,"phases":2089,"primaryCompletion":2068,"completion":2068,"start":2069,"enrollment":2070,"conditions":2090,"interventions":2091},[90],[1774],[2056,2073],{"trials":2093,"activeCount":100},[],{"trials":2095,"activeCount":100},[],{"trials":2097,"activeCount":100},[],{"intervention":2099,"totalTrials":96,"cells":2100},"Mirtazapine",{"EARLY_PHASE1":2101,"PHASE1":2103,"PHASE2":2105,"PHASE3":2117,"PHASE4":2119,"NA":2121},{"trials":2102,"activeCount":100},[],{"trials":2104,"activeCount":100},[],{"trials":2106,"activeCount":100},[2107],{"nctId":2108,"briefTitle":2109,"status":186,"phases":2110,"primaryCompletion":2111,"completion":2111,"start":2112,"enrollment":276,"conditions":2113,"interventions":2115},"NCT01165541","A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency",[90],"2012-10","2010-09",[2114],"Alcohol Dependence",[2099,2116],"Quetiapine fumarate extended release",{"trials":2118,"activeCount":100},[],{"trials":2120,"activeCount":100},[],{"trials":2122,"activeCount":100},[],{"intervention":2116,"totalTrials":96,"cells":2124},{"EARLY_PHASE1":2125,"PHASE1":2127,"PHASE2":2129,"PHASE3":2135,"PHASE4":2137,"NA":2139},{"trials":2126,"activeCount":100},[],{"trials":2128,"activeCount":100},[],{"trials":2130,"activeCount":100},[2131],{"nctId":2108,"briefTitle":2109,"status":186,"phases":2132,"primaryCompletion":2111,"completion":2111,"start":2112,"enrollment":276,"conditions":2133,"interventions":2134},[90],[2114],[2099,2116],{"trials":2136,"activeCount":100},[],{"trials":2138,"activeCount":100},[],{"trials":2140,"activeCount":100},[],{"intervention":1812,"totalTrials":96,"cells":2142},{"EARLY_PHASE1":2143,"PHASE1":2145,"PHASE2":2147,"PHASE3":2153,"PHASE4":2155,"NA":2157},{"trials":2144,"activeCount":100},[],{"trials":2146,"activeCount":100},[],{"trials":2148,"activeCount":100},[2149],{"nctId":1804,"briefTitle":1805,"status":186,"phases":2150,"primaryCompletion":994,"completion":1807,"start":1808,"enrollment":19,"conditions":2151,"interventions":2152},[90],[1810],[1812,1795],{"trials":2154,"activeCount":100},[],{"trials":2156,"activeCount":100},[],{"trials":2158,"activeCount":100},[],{"intervention":171,"totalTrials":96,"cells":2160},{"EARLY_PHASE1":2161,"PHASE1":2163,"PHASE2":2165,"PHASE3":2171,"PHASE4":2173,"NA":2175},{"trials":2162,"activeCount":100},[],{"trials":2164,"activeCount":100},[],{"trials":2166,"activeCount":100},[2167],{"nctId":158,"briefTitle":159,"status":160,"phases":2168,"primaryCompletion":162,"completion":163,"start":164,"enrollment":100,"conditions":2169,"interventions":2170},[90],[166,167,168,169],[171,172,145],{"trials":2172,"activeCount":100},[],{"trials":2174,"activeCount":100},[],{"trials":2176,"activeCount":100},[],{"intervention":172,"totalTrials":96,"cells":2178},{"EARLY_PHASE1":2179,"PHASE1":2181,"PHASE2":2183,"PHASE3":2189,"PHASE4":2191,"NA":2193},{"trials":2180,"activeCount":100},[],{"trials":2182,"activeCount":100},[],{"trials":2184,"activeCount":100},[2185],{"nctId":158,"briefTitle":159,"status":160,"phases":2186,"primaryCompletion":162,"completion":163,"start":164,"enrollment":100,"conditions":2187,"interventions":2188},[90],[166,167,168,169],[171,172,145],{"trials":2190,"activeCount":100},[],{"trials":2192,"activeCount":100},[],{"trials":2194,"activeCount":100},[],{"intervention":2196,"totalTrials":96,"cells":2197},"Promethazine",{"EARLY_PHASE1":2198,"PHASE1":2200,"PHASE2":2202,"PHASE3":2214,"PHASE4":2216,"NA":2218},{"trials":2199,"activeCount":100},[],{"trials":2201,"activeCount":100},[],{"trials":2203,"activeCount":100},[2204],{"nctId":2205,"briefTitle":2206,"status":287,"phases":2207,"primaryCompletion":2208,"completion":2208,"start":2209,"enrollment":149,"conditions":2210,"interventions":2212},"NCT02130622","Study of Promethazine for Treatment of Diabetic Gastroparesis",[90],"2015-05-14","2014-07",[2211],"Diabetic Gastroparesis",[2196,2213],"Sugar pill",{"trials":2215,"activeCount":100},[],{"trials":2217,"activeCount":100},[],{"trials":2219,"activeCount":100},[],{"intervention":2213,"totalTrials":96,"cells":2221},{"EARLY_PHASE1":2222,"PHASE1":2224,"PHASE2":2226,"PHASE3":2232,"PHASE4":2234,"NA":2236},{"trials":2223,"activeCount":100},[],{"trials":2225,"activeCount":100},[],{"trials":2227,"activeCount":100},[2228],{"nctId":2205,"briefTitle":2206,"status":287,"phases":2229,"primaryCompletion":2208,"completion":2208,"start":2209,"enrollment":149,"conditions":2230,"interventions":2231},[90],[2211],[2196,2213],{"trials":2233,"activeCount":100},[],{"trials":2235,"activeCount":100},[],{"trials":2237,"activeCount":100},[],{"intervention":2239,"totalTrials":96,"cells":2240},"Twinrix",{"EARLY_PHASE1":2241,"PHASE1":2243,"PHASE2":2245,"PHASE3":2256,"PHASE4":2258,"NA":2260},{"trials":2242,"activeCount":100},[],{"trials":2244,"activeCount":100},[],{"trials":2246,"activeCount":100},[2247],{"nctId":2248,"briefTitle":2249,"status":186,"phases":2250,"primaryCompletion":2251,"completion":2252,"start":1948,"enrollment":2253,"conditions":2254,"interventions":2255},"NCT00316303","Effectiveness of the Screen, Test, Immunize, Reduce Risk, and Refer (STIRR) Intervention for People With Both a Mental and Substance Abuse Disorder",[90],"2009-04","2012-08",236,[1613,15,21,26,24,946],[2239],{"trials":2257,"activeCount":100},[],{"trials":2259,"activeCount":100},[],{"trials":2261,"activeCount":100},[],{"intervention":1902,"totalTrials":96,"cells":2263},{"EARLY_PHASE1":2264,"PHASE1":2266,"PHASE2":2268,"PHASE3":2274,"PHASE4":2276,"NA":2278},{"trials":2265,"activeCount":100},[],{"trials":2267,"activeCount":100},[],{"trials":2269,"activeCount":100},[2270],{"nctId":1895,"briefTitle":1896,"status":186,"phases":2271,"primaryCompletion":1898,"completion":1898,"start":1885,"enrollment":1899,"conditions":2272,"interventions":2273},[90],[1612],[1875,1902],{"trials":2275,"activeCount":100},[],{"trials":2277,"activeCount":100},[],{"trials":2279,"activeCount":100},[],{"intervention":280,"totalTrials":96,"cells":2281},{"EARLY_PHASE1":2282,"PHASE1":2284,"PHASE2":2286,"PHASE3":2292,"PHASE4":2294,"NA":2296},{"trials":2283,"activeCount":100},[],{"trials":2285,"activeCount":100},[],{"trials":2287,"activeCount":100},[2288],{"nctId":270,"briefTitle":271,"status":186,"phases":2289,"primaryCompletion":273,"completion":274,"start":275,"enrollment":276,"conditions":2290,"interventions":2291},[90],[278],[280,281,282,283],{"trials":2293,"activeCount":100},[],{"trials":2295,"activeCount":100},[],{"trials":2297,"activeCount":100},[],{"intervention":283,"totalTrials":96,"cells":2299},{"EARLY_PHASE1":2300,"PHASE1":2302,"PHASE2":2304,"PHASE3":2310,"PHASE4":2312,"NA":2314},{"trials":2301,"activeCount":100},[],{"trials":2303,"activeCount":100},[],{"trials":2305,"activeCount":100},[2306],{"nctId":270,"briefTitle":271,"status":186,"phases":2307,"primaryCompletion":273,"completion":274,"start":275,"enrollment":276,"conditions":2308,"interventions":2309},[90],[278],[280,281,282,283],{"trials":2311,"activeCount":100},[],{"trials":2313,"activeCount":100},[],{"trials":2315,"activeCount":100},[],{"intervention":2317,"totalTrials":96,"cells":2318},"17B-estradiol",{"EARLY_PHASE1":2319,"PHASE1":2321,"PHASE2":2323,"PHASE3":2337,"PHASE4":2339,"NA":2341},{"trials":2320,"activeCount":100},[],{"trials":2322,"activeCount":100},[],{"trials":2324,"activeCount":100},[2325],{"nctId":2326,"briefTitle":2327,"status":186,"phases":2328,"primaryCompletion":2329,"completion":2330,"start":2331,"enrollment":995,"conditions":2332,"interventions":2333},"NCT02188745","ER Reactivation Therapy for Breast Cancer",[90],"2024-01-05","2024-07-05","2016-03-11",[380],[2317,2334,2335,2336],"Letrozole","Anastrozole","Exemestane",{"trials":2338,"activeCount":100},[],{"trials":2340,"activeCount":100},[],{"trials":2342,"activeCount":100},[],{"intervention":2335,"totalTrials":96,"cells":2344},{"EARLY_PHASE1":2345,"PHASE1":2347,"PHASE2":2349,"PHASE3":2355,"PHASE4":2357,"NA":2359},{"trials":2346,"activeCount":100},[],{"trials":2348,"activeCount":100},[],{"trials":2350,"activeCount":100},[2351],{"nctId":2326,"briefTitle":2327,"status":186,"phases":2352,"primaryCompletion":2329,"completion":2330,"start":2331,"enrollment":995,"conditions":2353,"interventions":2354},[90],[380],[2317,2334,2335,2336],{"trials":2356,"activeCount":100},[],{"trials":2358,"activeCount":100},[],{"trials":2360,"activeCount":100},[],{"intervention":2336,"totalTrials":96,"cells":2362},{"EARLY_PHASE1":2363,"PHASE1":2365,"PHASE2":2367,"PHASE3":2373,"PHASE4":2375,"NA":2377},{"trials":2364,"activeCount":100},[],{"trials":2366,"activeCount":100},[],{"trials":2368,"activeCount":100},[2369],{"nctId":2326,"briefTitle":2327,"status":186,"phases":2370,"primaryCompletion":2329,"completion":2330,"start":2331,"enrollment":995,"conditions":2371,"interventions":2372},[90],[380],[2317,2334,2335,2336],{"trials":2374,"activeCount":100},[],{"trials":2376,"activeCount":100},[],{"trials":2378,"activeCount":100},[],{"intervention":1963,"totalTrials":96,"cells":2380},{"EARLY_PHASE1":2381,"PHASE1":2383,"PHASE2":2385,"PHASE3":2391,"PHASE4":2393,"NA":2395},{"trials":2382,"activeCount":100},[],{"trials":2384,"activeCount":100},[],{"trials":2386,"activeCount":100},[2387],{"nctId":1955,"briefTitle":1956,"status":186,"phases":2388,"primaryCompletion":1958,"completion":1958,"start":1959,"enrollment":313,"conditions":2389,"interventions":2390},[90],[1961],[1963,1938,1964],{"trials":2392,"activeCount":100},[],{"trials":2394,"activeCount":100},[],{"trials":2396,"activeCount":100},[],{"intervention":1964,"totalTrials":96,"cells":2398},{"EARLY_PHASE1":2399,"PHASE1":2401,"PHASE2":2403,"PHASE3":2409,"PHASE4":2411,"NA":2413},{"trials":2400,"activeCount":100},[],{"trials":2402,"activeCount":100},[],{"trials":2404,"activeCount":100},[2405],{"nctId":1955,"briefTitle":1956,"status":186,"phases":2406,"primaryCompletion":1958,"completion":1958,"start":1959,"enrollment":313,"conditions":2407,"interventions":2408},[90],[1961],[1963,1938,1964],{"trials":2410,"activeCount":100},[],{"trials":2412,"activeCount":100},[],{"trials":2414,"activeCount":100},[],{"intervention":2416,"totalTrials":96,"cells":2417},"Ex-vivo expanded effector cells",{"EARLY_PHASE1":2418,"PHASE1":2420,"PHASE2":2422,"PHASE3":2434,"PHASE4":2436,"NA":2438},{"trials":2419,"activeCount":100},[],{"trials":2421,"activeCount":100},[],{"trials":2423,"activeCount":100},[2424],{"nctId":2425,"briefTitle":2426,"status":186,"phases":2427,"primaryCompletion":2428,"completion":2429,"start":1408,"enrollment":378,"conditions":2430,"interventions":2433},"NCT00439465","Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma",[90],"2012-10-15","2012-11-30",[2431,2432],"Myeloma","Transplant-eligible Patients",[2416],{"trials":2435,"activeCount":100},[],{"trials":2437,"activeCount":100},[],{"trials":2439,"activeCount":100},[],{"intervention":1776,"totalTrials":96,"cells":2441},{"EARLY_PHASE1":2442,"PHASE1":2444,"PHASE2":2446,"PHASE3":2452,"PHASE4":2454,"NA":2456},{"trials":2443,"activeCount":100},[],{"trials":2445,"activeCount":100},[],{"trials":2447,"activeCount":100},[2448],{"nctId":1769,"briefTitle":1770,"status":287,"phases":2449,"primaryCompletion":289,"completion":289,"start":1772,"enrollment":1680,"conditions":2450,"interventions":2451},[90],[1774],[1776,1752,1777,1778],{"trials":2453,"activeCount":100},[],{"trials":2455,"activeCount":100},[],{"trials":2457,"activeCount":100},[],{"intervention":1778,"totalTrials":96,"cells":2459},{"EARLY_PHASE1":2460,"PHASE1":2462,"PHASE2":2464,"PHASE3":2470,"PHASE4":2472,"NA":2474},{"trials":2461,"activeCount":100},[],{"trials":2463,"activeCount":100},[],{"trials":2465,"activeCount":100},[2466],{"nctId":1769,"briefTitle":1770,"status":287,"phases":2467,"primaryCompletion":289,"completion":289,"start":1772,"enrollment":1680,"conditions":2468,"interventions":2469},[90],[1774],[1776,1752,1777,1778],{"trials":2471,"activeCount":100},[],{"trials":2473,"activeCount":100},[],{"trials":2475,"activeCount":100},[],{"intervention":295,"totalTrials":96,"cells":2477},{"EARLY_PHASE1":2478,"PHASE1":2480,"PHASE2":2482,"PHASE3":2488,"PHASE4":2490,"NA":2492},{"trials":2479,"activeCount":100},[],{"trials":2481,"activeCount":100},[],{"trials":2483,"activeCount":100},[2484],{"nctId":285,"briefTitle":286,"status":287,"phases":2485,"primaryCompletion":289,"completion":289,"start":290,"enrollment":291,"conditions":2486,"interventions":2487},[90],[293],[295,41,296],{"trials":2489,"activeCount":100},[],{"trials":2491,"activeCount":100},[],{"trials":2493,"activeCount":100},[],{"intervention":296,"totalTrials":96,"cells":2495},{"EARLY_PHASE1":2496,"PHASE1":2498,"PHASE2":2500,"PHASE3":2506,"PHASE4":2508,"NA":2510},{"trials":2497,"activeCount":100},[],{"trials":2499,"activeCount":100},[],{"trials":2501,"activeCount":100},[2502],{"nctId":285,"briefTitle":286,"status":287,"phases":2503,"primaryCompletion":289,"completion":289,"start":290,"enrollment":291,"conditions":2504,"interventions":2505},[90],[293],[295,41,296],{"trials":2507,"activeCount":100},[],{"trials":2509,"activeCount":100},[],{"trials":2511,"activeCount":100},[],{"intervention":2513,"totalTrials":96,"cells":2514},"Pancrelipase",{"EARLY_PHASE1":2515,"PHASE1":2517,"PHASE2":2519,"PHASE3":2530,"PHASE4":2532,"NA":2534},{"trials":2516,"activeCount":100},[],{"trials":2518,"activeCount":100},[],{"trials":2520,"activeCount":100},[2521],{"nctId":2522,"briefTitle":2523,"status":160,"phases":2524,"primaryCompletion":2525,"completion":2525,"start":2526,"enrollment":100,"conditions":2527,"interventions":2529},"NCT02706236","Trial of Pancreatic Enzyme Supplements (Pancrelipase) for Treating Pain in Patients With Chronic Pancreatitis",[90],"2018-12","2016-04",[2528],"Pancreatitis",[2513],{"trials":2531,"activeCount":100},[],{"trials":2533,"activeCount":100},[],{"trials":2535,"activeCount":100},[],{"intervention":2537,"totalTrials":96,"cells":2538},"gefitinib",{"EARLY_PHASE1":2539,"PHASE1":2541,"PHASE2":2543,"PHASE3":2554,"PHASE4":2556,"NA":2558},{"trials":2540,"activeCount":100},[],{"trials":2542,"activeCount":100},[],{"trials":2544,"activeCount":100},[2545],{"nctId":2546,"briefTitle":2547,"status":186,"phases":2548,"primaryCompletion":2549,"completion":2550,"start":1335,"enrollment":444,"conditions":2551,"interventions":2552},"NCT00080743","Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer",[90],"2005-04","2005-11",[18],[2537,2553],"tamoxifen citrate",{"trials":2555,"activeCount":100},[],{"trials":2557,"activeCount":100},[],{"trials":2559,"activeCount":100},[],{"intervention":2553,"totalTrials":96,"cells":2561},{"EARLY_PHASE1":2562,"PHASE1":2564,"PHASE2":2566,"PHASE3":2572,"PHASE4":2574,"NA":2576},{"trials":2563,"activeCount":100},[],{"trials":2565,"activeCount":100},[],{"trials":2567,"activeCount":100},[2568],{"nctId":2546,"briefTitle":2547,"status":186,"phases":2569,"primaryCompletion":2549,"completion":2550,"start":1335,"enrollment":444,"conditions":2570,"interventions":2571},[90],[18],[2537,2553],{"trials":2573,"activeCount":100},[],{"trials":2575,"activeCount":100},[],{"trials":2577,"activeCount":100},[],{"intervention":2579,"totalTrials":96,"cells":2580},"Cetuximab\u002FGemcitabine",{"EARLY_PHASE1":2581,"PHASE1":2583,"PHASE2":2585,"PHASE3":2594,"PHASE4":2596,"NA":2598},{"trials":2582,"activeCount":100},[],{"trials":2584,"activeCount":100},[],{"trials":2586,"activeCount":100},[2587],{"nctId":2588,"briefTitle":2589,"status":186,"phases":2590,"primaryCompletion":274,"completion":2591,"start":1818,"enrollment":2070,"conditions":2592,"interventions":2593},"NCT00225784","Cetuximab, Radiotherapy and Twice Weekly Gemcitabine to Treat Pancreatic Cancer",[90],"2012-09",[1849],[2579],{"trials":2595,"activeCount":100},[],{"trials":2597,"activeCount":100},[],{"trials":2599,"activeCount":100},[],{"intervention":2601,"totalTrials":96,"cells":2602},"Lenalidomide",{"EARLY_PHASE1":2603,"PHASE1":2605,"PHASE2":2607,"PHASE3":2618,"PHASE4":2620,"NA":2622},{"trials":2604,"activeCount":100},[],{"trials":2606,"activeCount":100},[],{"trials":2608,"activeCount":100},[2609],{"nctId":2610,"briefTitle":2611,"status":287,"phases":2612,"primaryCompletion":2613,"completion":2613,"start":1652,"enrollment":1680,"conditions":2614,"interventions":2617},"NCT00665652","Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance",[90],"2011-05-19",[2615,2616],"Neuropathy","Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS)",[2601],{"trials":2619,"activeCount":100},[],{"trials":2621,"activeCount":100},[],{"trials":2623,"activeCount":100},[],{"intervention":2625,"totalTrials":96,"cells":2626},"ACTHAR",{"EARLY_PHASE1":2627,"PHASE1":2629,"PHASE2":2631,"PHASE3":2643,"PHASE4":2645,"NA":2647},{"trials":2628,"activeCount":100},[],{"trials":2630,"activeCount":100},[],{"trials":2632,"activeCount":100},[2633],{"nctId":2634,"briefTitle":2635,"status":287,"phases":2636,"primaryCompletion":2637,"completion":2637,"start":2638,"enrollment":2639,"conditions":2640,"interventions":2642},"NCT01984268","ACTHAR for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate",[90],"2016-09-01","2014-06-23",15,[2641],"Rheumatoid Arthritis",[2625],{"trials":2644,"activeCount":100},[],{"trials":2646,"activeCount":100},[],{"trials":2648,"activeCount":100},[],{"intervention":2650,"totalTrials":96,"cells":2651},"paclitaxel poliglumex, pemetrexed",{"EARLY_PHASE1":2652,"PHASE1":2654,"PHASE2":2656,"PHASE3":2667,"PHASE4":2669,"NA":2671},{"trials":2653,"activeCount":100},[],{"trials":2655,"activeCount":100},[],{"trials":2657,"activeCount":100},[2658],{"nctId":2659,"briefTitle":2660,"status":186,"phases":2661,"primaryCompletion":2662,"completion":2662,"start":2663,"enrollment":9,"conditions":2664,"interventions":2666},"NCT00487669","Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC)",[90],"2009-11","2006-10",[2665],"Advanced Non-small Cell Lung Cancer",[2650],{"trials":2668,"activeCount":100},[],{"trials":2670,"activeCount":100},[],{"trials":2672,"activeCount":100},[],{"intervention":2674,"totalTrials":96,"cells":2675},"Iressa",{"EARLY_PHASE1":2676,"PHASE1":2678,"PHASE2":2680,"PHASE3":2691,"PHASE4":2693,"NA":2695},{"trials":2677,"activeCount":100},[],{"trials":2679,"activeCount":100},[],{"trials":2681,"activeCount":100},[2682],{"nctId":2683,"briefTitle":2684,"status":186,"phases":2685,"primaryCompletion":1408,"completion":1408,"start":2686,"enrollment":2687,"conditions":2688,"interventions":2690},"NCT00215202","Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)",[90],"2004-08",16,[2689],"Nonresectable Adrenocortical Carcinoma",[2674],{"trials":2692,"activeCount":100},[],{"trials":2694,"activeCount":100},[],{"trials":2696,"activeCount":100},[],{"intervention":1657,"totalTrials":96,"cells":2698},{"EARLY_PHASE1":2699,"PHASE1":2701,"PHASE2":2703,"PHASE3":2709,"PHASE4":2711,"NA":2713},{"trials":2700,"activeCount":100},[],{"trials":2702,"activeCount":100},[],{"trials":2704,"activeCount":100},[2705],{"nctId":1649,"briefTitle":1650,"status":186,"phases":2706,"primaryCompletion":1652,"completion":1653,"start":1479,"enrollment":35,"conditions":2707,"interventions":2708},[90],[1655],[1657,1658,1659],{"trials":2710,"activeCount":100},[],{"trials":2712,"activeCount":100},[],{"trials":2714,"activeCount":100},[],{"intervention":1659,"totalTrials":96,"cells":2716},{"EARLY_PHASE1":2717,"PHASE1":2719,"PHASE2":2721,"PHASE3":2727,"PHASE4":2729,"NA":2731},{"trials":2718,"activeCount":100},[],{"trials":2720,"activeCount":100},[],{"trials":2722,"activeCount":100},[2723],{"nctId":1649,"briefTitle":1650,"status":186,"phases":2724,"primaryCompletion":1652,"completion":1653,"start":1479,"enrollment":35,"conditions":2725,"interventions":2726},[90],[1655],[1657,1658,1659],{"trials":2728,"activeCount":100},[],{"trials":2730,"activeCount":100},[],{"trials":2732,"activeCount":100},[],{"intervention":1866,"totalTrials":96,"cells":2734},{"EARLY_PHASE1":2735,"PHASE1":2737,"PHASE2":2739,"PHASE3":2745,"PHASE4":2747,"NA":2749},{"trials":2736,"activeCount":100},[],{"trials":2738,"activeCount":100},[],{"trials":2740,"activeCount":100},[2741],{"nctId":1858,"briefTitle":1859,"status":186,"phases":2742,"primaryCompletion":1861,"completion":1862,"start":1863,"enrollment":276,"conditions":2743,"interventions":2744},[90],[1810],[1831,1866,1867],{"trials":2746,"activeCount":100},[],{"trials":2748,"activeCount":100},[],{"trials":2750,"activeCount":100},[],{"intervention":1867,"totalTrials":96,"cells":2752},{"EARLY_PHASE1":2753,"PHASE1":2755,"PHASE2":2757,"PHASE3":2763,"PHASE4":2765,"NA":2767},{"trials":2754,"activeCount":100},[],{"trials":2756,"activeCount":100},[],{"trials":2758,"activeCount":100},[2759],{"nctId":1858,"briefTitle":1859,"status":186,"phases":2760,"primaryCompletion":1861,"completion":1862,"start":1863,"enrollment":276,"conditions":2761,"interventions":2762},[90],[1810],[1831,1866,1867],{"trials":2764,"activeCount":100},[],{"trials":2766,"activeCount":100},[],{"trials":2768,"activeCount":100},[],{"intervention":2770,"totalTrials":96,"cells":2771},"apremilast",{"EARLY_PHASE1":2772,"PHASE1":2774,"PHASE2":2776,"PHASE3":2787,"PHASE4":2789,"NA":2791},{"trials":2773,"activeCount":100},[],{"trials":2775,"activeCount":100},[],{"trials":2777,"activeCount":100},[2778],{"nctId":2779,"briefTitle":2780,"status":160,"phases":2781,"primaryCompletion":992,"completion":992,"start":2782,"enrollment":100,"conditions":2783,"interventions":2785},"NCT00997581","Apremilast Therapy for Acute Gouty Arthritis",[90],"2010-04",[2784],"Acute Gout",[2770,2786],"indomethacin SR",{"trials":2788,"activeCount":100},[],{"trials":2790,"activeCount":100},[],{"trials":2792,"activeCount":100},[],{"intervention":2786,"totalTrials":96,"cells":2794},{"EARLY_PHASE1":2795,"PHASE1":2797,"PHASE2":2799,"PHASE3":2805,"PHASE4":2807,"NA":2809},{"trials":2796,"activeCount":100},[],{"trials":2798,"activeCount":100},[],{"trials":2800,"activeCount":100},[2801],{"nctId":2779,"briefTitle":2780,"status":160,"phases":2802,"primaryCompletion":992,"completion":992,"start":2782,"enrollment":100,"conditions":2803,"interventions":2804},[90],[2784],[2770,2786],{"trials":2806,"activeCount":100},[],{"trials":2808,"activeCount":100},[],{"trials":2810,"activeCount":100},[],{"intervention":2812,"totalTrials":96,"cells":2813},"lepirudin",{"EARLY_PHASE1":2814,"PHASE1":2816,"PHASE2":2818,"PHASE3":2828,"PHASE4":2830,"NA":2832},{"trials":2815,"activeCount":100},[],{"trials":2817,"activeCount":100},[],{"trials":2819,"activeCount":100},[2820],{"nctId":2821,"briefTitle":2822,"status":287,"phases":2823,"primaryCompletion":2824,"completion":2824,"start":2825,"enrollment":96,"conditions":2826,"interventions":2827},"NCT00003726","Lepirudin in Treating Patients With Recurrent or Advanced Small Cell Lung Cancer",[89,90],"2001-07","1998-11",[1847],[2812],{"trials":2829,"activeCount":100},[],{"trials":2831,"activeCount":100},[],{"trials":2833,"activeCount":100},[],{"intervention":2835,"totalTrials":96,"cells":2836},"Risperidone + Desipramine",{"EARLY_PHASE1":2837,"PHASE1":2839,"PHASE2":2841,"PHASE3":2853,"PHASE4":2855,"NA":2857},{"trials":2838,"activeCount":100},[],{"trials":2840,"activeCount":100},[],{"trials":2842,"activeCount":100},[2843],{"nctId":2844,"briefTitle":2845,"status":186,"phases":2846,"primaryCompletion":2847,"completion":2848,"start":2849,"enrollment":32,"conditions":2850,"interventions":2852},"NCT01411085","Risperidone and Desipramine in Alcohol Use and Schizophrenia",[90],"2014-08","2014-09","2011-12",[15,2851,1065],"Alcoholism",[2835],{"trials":2854,"activeCount":100},[],{"trials":2856,"activeCount":100},[],{"trials":2858,"activeCount":100},[],{"intervention":2860,"totalTrials":444,"cells":2861},"Conjugated Linoleic Acid",{"EARLY_PHASE1":2862,"PHASE1":2871,"PHASE2":2883,"PHASE3":2885,"PHASE4":2887,"NA":2889},{"trials":2863,"activeCount":100},[2864],{"nctId":2865,"briefTitle":2866,"status":186,"phases":2867,"primaryCompletion":2868,"completion":2868,"start":1225,"enrollment":810,"conditions":2869,"interventions":2870},"NCT00908791","Proof of Principle Trial to Determine if Nutritional Supplement Conjugated Linoleic Acid (CLA) Can Modulate the Lipogenic Pathway in Breast Cancer Tissue",[88],"2013-03",[18],[2860],{"trials":2872,"activeCount":100},[2873],{"nctId":2874,"briefTitle":2875,"status":287,"phases":2876,"primaryCompletion":2877,"completion":2878,"start":1761,"enrollment":2879,"conditions":2880,"interventions":2882},"NCT00951158","A Molecular Pharmacodynamic Dose-titration Trial of Conjugated Linoleic Acid (CLA; Clarinol®) in Patients With Advanced Solid Tumors",[89],"2012-12","2013-06",4,[2881],"Advanced Solid Tumors",[2860],{"trials":2884,"activeCount":100},[],{"trials":2886,"activeCount":100},[],{"trials":2888,"activeCount":100},[],{"trials":2890,"activeCount":100},[],{"intervention":2892,"totalTrials":444,"cells":2893},"Dronabinol",{"EARLY_PHASE1":2894,"PHASE1":2896,"PHASE2":2916,"PHASE3":2918,"PHASE4":2920,"NA":2922},{"trials":2895,"activeCount":100},[],{"trials":2897,"activeCount":100},[2898,2908],{"nctId":2899,"briefTitle":2900,"status":186,"phases":2901,"primaryCompletion":2902,"completion":2902,"start":2209,"enrollment":2903,"conditions":2904,"interventions":2906},"NCT01964404","Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?",[89],"2021-09-18",263,[15,1065,945,2905],"Cannabis Use Disorder",[2907,2892],"Marijuana",{"nctId":2909,"briefTitle":2910,"status":186,"phases":2911,"primaryCompletion":2111,"completion":2111,"start":2912,"enrollment":32,"conditions":2913,"interventions":2914},"NCT00946348","Cannabis and Schizophrenia: Self-Medication and Agonist Treatment",[89],"2009-12",[15,1065,21,945,2905],[2892,2915],"Cannabis",{"trials":2917,"activeCount":100},[],{"trials":2919,"activeCount":100},[],{"trials":2921,"activeCount":100},[],{"trials":2923,"activeCount":100},[],{"intervention":460,"totalTrials":444,"cells":2925},{"EARLY_PHASE1":2926,"PHASE1":2928,"PHASE2":2944,"PHASE3":2946,"PHASE4":2948,"NA":2950},{"trials":2927,"activeCount":100},[],{"trials":2929,"activeCount":100},[2930,2940],{"nctId":2931,"briefTitle":2932,"status":160,"phases":2933,"primaryCompletion":2934,"completion":2934,"start":2935,"enrollment":100,"conditions":2936,"interventions":2938},"NCT03422874","Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma",[89],"2017-08-04","2016-08",[2937,220],"Neoplasms",[460,2939],"Nelfinavir",{"nctId":451,"briefTitle":452,"status":287,"phases":2941,"primaryCompletion":454,"completion":455,"start":456,"enrollment":457,"conditions":2942,"interventions":2943},[89],[18],[443,460],{"trials":2945,"activeCount":100},[],{"trials":2947,"activeCount":100},[],{"trials":2949,"activeCount":100},[],{"trials":2951,"activeCount":100},[],{"intervention":1853,"totalTrials":444,"cells":2953},{"EARLY_PHASE1":2954,"PHASE1":2956,"PHASE2":2966,"PHASE3":2968,"PHASE4":2970,"NA":2972},{"trials":2955,"activeCount":100},[],{"trials":2957,"activeCount":100},[2958,2962],{"nctId":1838,"briefTitle":1839,"status":186,"phases":2959,"primaryCompletion":1480,"completion":1480,"start":1841,"enrollment":658,"conditions":2960,"interventions":2961},[89],[1843,18,1844,1845,1846,790,1847,278,1848,1849,1850,1851],[1831,1853,1854],{"nctId":401,"briefTitle":402,"status":186,"phases":2963,"primaryCompletion":404,"completion":405,"start":406,"enrollment":32,"conditions":2964,"interventions":2965},[89],[380],[394,409],{"trials":2967,"activeCount":100},[],{"trials":2969,"activeCount":100},[],{"trials":2971,"activeCount":100},[],{"trials":2973,"activeCount":100},[],{"intervention":2975,"totalTrials":96,"cells":2976},"adenosine triphosphate",{"EARLY_PHASE1":2977,"PHASE1":2979,"PHASE2":2988,"PHASE3":2990,"PHASE4":2992,"NA":2994},{"trials":2978,"activeCount":100},[],{"trials":2980,"activeCount":100},[2981],{"nctId":2982,"briefTitle":2983,"status":186,"phases":2984,"primaryCompletion":1630,"start":1062,"conditions":2985,"interventions":2987},"NCT00014248","Adenosine Triphosphate in Treating Patients With Advanced Solid Tumors",[89],[2986,1632],"Cachexia",[2975],{"trials":2989,"activeCount":100},[],{"trials":2991,"activeCount":100},[],{"trials":2993,"activeCount":100},[],{"trials":2995,"activeCount":100},[],{"intervention":2997,"totalTrials":96,"cells":2998},"Hydroxyurea",{"EARLY_PHASE1":2999,"PHASE1":3001,"PHASE2":3010,"PHASE3":3012,"PHASE4":3014,"NA":3016},{"trials":3000,"activeCount":100},[],{"trials":3002,"activeCount":100},[3003],{"nctId":3004,"briefTitle":3005,"status":160,"phases":3006,"primaryCompletion":264,"completion":264,"start":3007,"enrollment":100,"conditions":3008,"interventions":3009},"NCT01521299","A Dose Escalation Study of Hydroxyurea in Combination With SCH900776 in Advanced Malignant Solid Tumors",[89],"2012-03",[2881],[2997],{"trials":3011,"activeCount":100},[],{"trials":3013,"activeCount":100},[],{"trials":3015,"activeCount":100},[],{"trials":3017,"activeCount":100},[],{"intervention":2907,"totalTrials":96,"cells":3019},{"EARLY_PHASE1":3020,"PHASE1":3022,"PHASE2":3028,"PHASE3":3030,"PHASE4":3032,"NA":3034},{"trials":3021,"activeCount":100},[],{"trials":3023,"activeCount":100},[3024],{"nctId":2899,"briefTitle":2900,"status":186,"phases":3025,"primaryCompletion":2902,"completion":2902,"start":2209,"enrollment":2903,"conditions":3026,"interventions":3027},[89],[15,1065,945,2905],[2907,2892],{"trials":3029,"activeCount":100},[],{"trials":3031,"activeCount":100},[],{"trials":3033,"activeCount":100},[],{"trials":3035,"activeCount":100},[],{"intervention":3037,"totalTrials":96,"cells":3038},"Tumor Vaccine",{"EARLY_PHASE1":3039,"PHASE1":3041,"PHASE2":3051,"PHASE3":3053,"PHASE4":3055,"NA":3057},{"trials":3040,"activeCount":100},[],{"trials":3042,"activeCount":100},[3043],{"nctId":3044,"briefTitle":3045,"status":287,"phases":3046,"primaryCompletion":3047,"completion":3047,"start":1270,"enrollment":96,"conditions":3048,"interventions":3050},"NCT01702792","Derivation of Tumor Specific Hybridomas",[89],"2015-05-06",[3049],"Glioblastoma",[3037],{"trials":3052,"activeCount":100},[],{"trials":3054,"activeCount":100},[],{"trials":3056,"activeCount":100},[],{"trials":3058,"activeCount":100},[],{"intervention":1634,"totalTrials":96,"cells":3060},{"EARLY_PHASE1":3061,"PHASE1":3063,"PHASE2":3069,"PHASE3":3071,"PHASE4":3073,"NA":3075},{"trials":3062,"activeCount":100},[],{"trials":3064,"activeCount":100},[3065],{"nctId":1627,"briefTitle":1628,"status":186,"phases":3066,"primaryCompletion":1630,"completion":1630,"start":1062,"conditions":3067,"interventions":3068},[89],[1632],[1634,1620],{"trials":3070,"activeCount":100},[],{"trials":3072,"activeCount":100},[],{"trials":3074,"activeCount":100},[],{"trials":3076,"activeCount":100},[],{"intervention":2939,"totalTrials":96,"cells":3078},{"EARLY_PHASE1":3079,"PHASE1":3081,"PHASE2":3087,"PHASE3":3089,"PHASE4":3091,"NA":3093},{"trials":3080,"activeCount":100},[],{"trials":3082,"activeCount":100},[3083],{"nctId":2931,"briefTitle":2932,"status":160,"phases":3084,"primaryCompletion":2934,"completion":2934,"start":2935,"enrollment":100,"conditions":3085,"interventions":3086},[89],[2937,220],[460,2939],{"trials":3088,"activeCount":100},[],{"trials":3090,"activeCount":100},[],{"trials":3092,"activeCount":100},[],{"trials":3094,"activeCount":100},[],{"intervention":1854,"totalTrials":96,"cells":3096},{"EARLY_PHASE1":3097,"PHASE1":3099,"PHASE2":3105,"PHASE3":3107,"PHASE4":3109,"NA":3111},{"trials":3098,"activeCount":100},[],{"trials":3100,"activeCount":100},[3101],{"nctId":1838,"briefTitle":1839,"status":186,"phases":3102,"primaryCompletion":1480,"completion":1480,"start":1841,"enrollment":658,"conditions":3103,"interventions":3104},[89],[1843,18,1844,1845,1846,790,1847,278,1848,1849,1850,1851],[1831,1853,1854],{"trials":3106,"activeCount":100},[],{"trials":3108,"activeCount":100},[],{"trials":3110,"activeCount":100},[],{"trials":3112,"activeCount":100},[],{"intervention":3114,"totalTrials":96,"cells":3115},"Scopolamine",{"EARLY_PHASE1":3116,"PHASE1":3118,"PHASE2":3129,"PHASE3":3131,"PHASE4":3133,"NA":3135},{"trials":3117,"activeCount":100},[],{"trials":3119,"activeCount":100},[3120],{"nctId":3121,"briefTitle":3122,"status":186,"phases":3123,"primaryCompletion":3124,"completion":3124,"start":3125,"enrollment":9,"conditions":3126,"interventions":3128},"NCT04999449","Nebulizer Delivery of Intranasal Scopolamine",[89],"2025-05-07","2022-01-24",[3114,3127],"Motion Sickness",[3114],{"trials":3130,"activeCount":100},[],{"trials":3132,"activeCount":100},[],{"trials":3134,"activeCount":100},[],{"trials":3136,"activeCount":100},[],{"intervention":1356,"totalTrials":96,"cells":3138},{"EARLY_PHASE1":3139,"PHASE1":3141,"PHASE2":3147,"PHASE3":3149,"PHASE4":3151,"NA":3153},{"trials":3140,"activeCount":100},[],{"trials":3142,"activeCount":100},[3143],{"nctId":1349,"briefTitle":1350,"status":186,"phases":3144,"primaryCompletion":1352,"start":1353,"enrollment":29,"conditions":3145,"interventions":3146},[89],[18],[382,1356],{"trials":3148,"activeCount":100},[],{"trials":3150,"activeCount":100},[],{"trials":3152,"activeCount":100},[],{"trials":3154,"activeCount":100},[],{"intervention":2915,"totalTrials":96,"cells":3156},{"EARLY_PHASE1":3157,"PHASE1":3159,"PHASE2":3165,"PHASE3":3167,"PHASE4":3169,"NA":3171},{"trials":3158,"activeCount":100},[],{"trials":3160,"activeCount":100},[3161],{"nctId":2909,"briefTitle":2910,"status":186,"phases":3162,"primaryCompletion":2111,"completion":2111,"start":2912,"enrollment":32,"conditions":3163,"interventions":3164},[89],[15,1065,21,945,2905],[2892,2915],{"trials":3166,"activeCount":100},[],{"trials":3168,"activeCount":100},[],{"trials":3170,"activeCount":100},[],{"trials":3172,"activeCount":100},[],{"intervention":3174,"totalTrials":96,"cells":3175},"Daratumumab \u002F Hyaluronidase",{"EARLY_PHASE1":3176,"PHASE1":3178,"PHASE2":3189,"PHASE3":3191,"PHASE4":3193,"NA":3195},{"trials":3177,"activeCount":100},[],{"trials":3179,"activeCount":100},[3180],{"nctId":3181,"briefTitle":3182,"status":186,"phases":3183,"primaryCompletion":3184,"completion":3184,"start":3185,"enrollment":444,"conditions":3186,"interventions":3188},"NCT05004259","The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic Anemia",[89],"2024-09-21","2022-03-21",[3187],"Hemolytic Anemia",[3174],{"trials":3190,"activeCount":100},[],{"trials":3192,"activeCount":100},[],{"trials":3194,"activeCount":100},[],{"trials":3196,"activeCount":100},[],{"intervention":1890,"totalTrials":96,"cells":3198},{"EARLY_PHASE1":3199,"PHASE1":3201,"PHASE2":3207,"PHASE3":3209,"PHASE4":3211,"NA":3213},{"trials":3200,"activeCount":100},[],{"trials":3202,"activeCount":100},[3203],{"nctId":1882,"briefTitle":1883,"status":186,"phases":3204,"primaryCompletion":1885,"completion":1505,"start":1886,"enrollment":1887,"conditions":3205,"interventions":3206},[89],[1612],[1875,1890,1891],{"trials":3208,"activeCount":100},[],{"trials":3210,"activeCount":100},[],{"trials":3212,"activeCount":100},[],{"trials":3214,"activeCount":100},[],{"intervention":1891,"totalTrials":96,"cells":3216},{"EARLY_PHASE1":3217,"PHASE1":3219,"PHASE2":3225,"PHASE3":3227,"PHASE4":3229,"NA":3231},{"trials":3218,"activeCount":100},[],{"trials":3220,"activeCount":100},[3221],{"nctId":1882,"briefTitle":1883,"status":186,"phases":3222,"primaryCompletion":1885,"completion":1505,"start":1886,"enrollment":1887,"conditions":3223,"interventions":3224},[89],[1612],[1875,1890,1891],{"trials":3226,"activeCount":100},[],{"trials":3228,"activeCount":100},[],{"trials":3230,"activeCount":100},[],{"trials":3232,"activeCount":100},[],{"intervention":1728,"totalTrials":96,"cells":3234},{"EARLY_PHASE1":3235,"PHASE1":3237,"PHASE2":3243,"PHASE3":3245,"PHASE4":3247,"NA":3249},{"trials":3236,"activeCount":100},[],{"trials":3238,"activeCount":100},[3239],{"nctId":1720,"briefTitle":1721,"status":186,"phases":3240,"primaryCompletion":1723,"completion":1723,"start":1724,"enrollment":11,"conditions":3241,"interventions":3242},[89],[1726],[281,1728,1729],{"trials":3244,"activeCount":100},[],{"trials":3246,"activeCount":100},[],{"trials":3248,"activeCount":100},[],{"trials":3250,"activeCount":100},[],{"intervention":1729,"totalTrials":96,"cells":3252},{"EARLY_PHASE1":3253,"PHASE1":3255,"PHASE2":3261,"PHASE3":3263,"PHASE4":3265,"NA":3267},{"trials":3254,"activeCount":100},[],{"trials":3256,"activeCount":100},[3257],{"nctId":1720,"briefTitle":1721,"status":186,"phases":3258,"primaryCompletion":1723,"completion":1723,"start":1724,"enrollment":11,"conditions":3259,"interventions":3260},[89],[1726],[281,1728,1729],{"trials":3262,"activeCount":100},[],{"trials":3264,"activeCount":100},[],{"trials":3266,"activeCount":100},[],{"trials":3268,"activeCount":100},[],{"intervention":1738,"totalTrials":96,"cells":3270},{"EARLY_PHASE1":3271,"PHASE1":3273,"PHASE2":3279,"PHASE3":3281,"PHASE4":3283,"NA":3285},{"trials":3272,"activeCount":100},[],{"trials":3274,"activeCount":100},[3275],{"nctId":1731,"briefTitle":1732,"status":287,"phases":3276,"primaryCompletion":1734,"completion":1734,"start":1735,"enrollment":149,"conditions":3277,"interventions":3278},[89],[1726,220],[1738,281],{"trials":3280,"activeCount":100},[],{"trials":3282,"activeCount":100},[],{"trials":3284,"activeCount":100},[],{"trials":3286,"activeCount":100},[],{"intervention":1951,"totalTrials":96,"cells":3288},{"EARLY_PHASE1":3289,"PHASE1":3291,"PHASE2":3297,"PHASE3":3299,"PHASE4":3301,"NA":3303},{"trials":3290,"activeCount":100},[],{"trials":3292,"activeCount":100},[3293],{"nctId":1945,"briefTitle":1946,"status":186,"phases":3294,"primaryCompletion":1948,"completion":1948,"start":275,"conditions":3295,"interventions":3296},[89],[278],[1938,1951],{"trials":3298,"activeCount":100},[],{"trials":3300,"activeCount":100},[],{"trials":3302,"activeCount":100},[],{"trials":3304,"activeCount":100},[],{"intervention":3306,"totalTrials":96,"cells":3307},"bispecific antibody MDX447",{"EARLY_PHASE1":3308,"PHASE1":3310,"PHASE2":3320,"PHASE3":3322,"PHASE4":3324,"NA":3326},{"trials":3309,"activeCount":100},[],{"trials":3311,"activeCount":100},[3312],{"nctId":3313,"briefTitle":3314,"status":186,"phases":3315,"primaryCompletion":406,"completion":406,"start":3316,"conditions":3317,"interventions":3318},"NCT00005813","Bispecific Antibody Plus White Blood Cells in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme",[89],"1997-03",[1810],[3306,3319],"lymphokine-activated killer cells",{"trials":3321,"activeCount":100},[],{"trials":3323,"activeCount":100},[],{"trials":3325,"activeCount":100},[],{"trials":3327,"activeCount":100},[],{"intervention":3319,"totalTrials":96,"cells":3329},{"EARLY_PHASE1":3330,"PHASE1":3332,"PHASE2":3338,"PHASE3":3340,"PHASE4":3342,"NA":3344},{"trials":3331,"activeCount":100},[],{"trials":3333,"activeCount":100},[3334],{"nctId":3313,"briefTitle":3314,"status":186,"phases":3335,"primaryCompletion":406,"completion":406,"start":3316,"conditions":3336,"interventions":3337},[89],[1810],[3306,3319],{"trials":3339,"activeCount":100},[],{"trials":3341,"activeCount":100},[],{"trials":3343,"activeCount":100},[],{"trials":3345,"activeCount":100},[],{"intervention":3347,"totalTrials":96,"cells":3348},"ALA-induced Fluorescence",{"EARLY_PHASE1":3349,"PHASE1":3351,"PHASE2":3360,"PHASE3":3362,"PHASE4":3364,"NA":3366},{"trials":3350,"activeCount":100},[],{"trials":3352,"activeCount":100},[3353],{"nctId":3354,"briefTitle":3355,"status":160,"phases":3356,"primaryCompletion":2209,"completion":2209,"start":290,"enrollment":100,"conditions":3357,"interventions":3359},"NCT01611584","A Proof of Principle Study of Aminolevulinic Acid (ALA) - Induced Fluorescence Detection in Resectable Non-Small Cell Lung Cancer",[89],[3358],"Lung Cancer in Normal and Malignant Tumors",[3347],{"trials":3361,"activeCount":100},[],{"trials":3363,"activeCount":100},[],{"trials":3365,"activeCount":100},[],{"trials":3367,"activeCount":100},[],{"intervention":2020,"totalTrials":96,"cells":3369},{"EARLY_PHASE1":3370,"PHASE1":3372,"PHASE2":3378,"PHASE3":3380,"PHASE4":3382,"NA":3384},{"trials":3371,"activeCount":100},[],{"trials":3373,"activeCount":100},[3374],{"nctId":2011,"briefTitle":2012,"status":186,"phases":3375,"primaryCompletion":2014,"completion":2014,"start":406,"enrollment":29,"conditions":3376,"interventions":3377},[89],[2016,2017,337,2018,1726],[2020,1777],{"trials":3379,"activeCount":100},[],{"trials":3381,"activeCount":100},[],{"trials":3383,"activeCount":100},[],{"trials":3385,"activeCount":100},[],{"intervention":3387,"totalTrials":96,"cells":3388},"Aprotinin",{"EARLY_PHASE1":3389,"PHASE1":3391,"PHASE2":3401,"PHASE3":3403,"PHASE4":3405,"NA":3407},{"trials":3390,"activeCount":100},[],{"trials":3392,"activeCount":100},[3393],{"nctId":3394,"briefTitle":3395,"status":287,"phases":3396,"completion":3397,"start":3398,"enrollment":313,"conditions":3399,"interventions":3400},"NCT00354900","Phase I Study of Aprotinin in Advanced Breast Cancer",[89],"2007-04","2006-07",[380],[3387],{"trials":3402,"activeCount":100},[],{"trials":3404,"activeCount":100},[],{"trials":3406,"activeCount":100},[],{"trials":3408,"activeCount":100},[],{"intervention":340,"totalTrials":96,"cells":3410},{"EARLY_PHASE1":3411,"PHASE1":3413,"PHASE2":3419,"PHASE3":3421,"PHASE4":3423,"NA":3425},{"trials":3412,"activeCount":100},[],{"trials":3414,"activeCount":100},[3415],{"nctId":326,"briefTitle":327,"status":186,"phases":3416,"primaryCompletion":329,"completion":330,"start":331,"enrollment":276,"conditions":3417,"interventions":3418},[89],[333,334,335,219,336,337,338],[224,340,341,318],{"trials":3420,"activeCount":100},[],{"trials":3422,"activeCount":100},[],{"trials":3424,"activeCount":100},[],{"trials":3426,"activeCount":100},[],{"intervention":341,"totalTrials":96,"cells":3428},{"EARLY_PHASE1":3429,"PHASE1":3431,"PHASE2":3437,"PHASE3":3439,"PHASE4":3441,"NA":3443},{"trials":3430,"activeCount":100},[],{"trials":3432,"activeCount":100},[3433],{"nctId":326,"briefTitle":327,"status":186,"phases":3434,"primaryCompletion":329,"completion":330,"start":331,"enrollment":276,"conditions":3435,"interventions":3436},[89],[333,334,335,219,336,337,338],[224,340,341,318],{"trials":3438,"activeCount":100},[],{"trials":3440,"activeCount":100},[],{"trials":3442,"activeCount":100},[],{"trials":3444,"activeCount":100},[],{"intervention":1924,"totalTrials":96,"cells":3446},{"EARLY_PHASE1":3447,"PHASE1":3449,"PHASE2":3455,"PHASE3":3457,"PHASE4":3459,"NA":3461},{"trials":3448,"activeCount":100},[],{"trials":3450,"activeCount":100},[3451],{"nctId":1916,"briefTitle":1917,"status":186,"phases":3452,"primaryCompletion":1919,"completion":1919,"start":1920,"enrollment":1921,"conditions":3453,"interventions":3454},[89],[215],[1924,1696],{"trials":3456,"activeCount":100},[],{"trials":3458,"activeCount":100},[],{"trials":3460,"activeCount":100},[],{"trials":3462,"activeCount":100},[],{"intervention":3464,"totalTrials":96,"cells":3465},"Deucravacitinib",{"EARLY_PHASE1":3466,"PHASE1":3476,"PHASE2":3478,"PHASE3":3480,"PHASE4":3482,"NA":3484},{"trials":3467,"activeCount":100},[3468],{"nctId":3469,"briefTitle":3470,"status":160,"phases":3471,"primaryCompletion":3472,"completion":3472,"start":3472,"enrollment":100,"conditions":3473,"interventions":3475},"NCT05821374","Deucravacitinib in PG",[88],"2024-04-29",[3474],"Pyoderma Gangrenosum",[3464],{"trials":3477,"activeCount":100},[],{"trials":3479,"activeCount":100},[],{"trials":3481,"activeCount":100},[],{"trials":3483,"activeCount":100},[],{"trials":3485,"activeCount":100},[],{"intervention":3487,"totalTrials":96,"cells":3488},"Avastin",{"EARLY_PHASE1":3489,"PHASE1":3501,"PHASE2":3503,"PHASE3":3505,"PHASE4":3507,"NA":3509},{"trials":3490,"activeCount":100},[3491],{"nctId":3492,"briefTitle":3493,"status":287,"phases":3494,"primaryCompletion":3495,"completion":3496,"start":2912,"enrollment":96,"conditions":3497,"interventions":3500},"NCT01015300","Bevacizumab (Avastin) in Unresectable\u002FRecurrent Hemangioblastoma From Von-Hippel-Lindau Disease",[88],"2011-10","2012-04",[3498,3499],"Hemangioblastomas","Von Hippel Lindau Disease",[3487],{"trials":3502,"activeCount":100},[],{"trials":3504,"activeCount":100},[],{"trials":3506,"activeCount":100},[],{"trials":3508,"activeCount":100},[],{"trials":3510,"activeCount":100},[],{"intervention":3512,"totalTrials":96,"cells":3513},"Indocyanine Green",{"EARLY_PHASE1":3514,"PHASE1":3525,"PHASE2":3527,"PHASE3":3529,"PHASE4":3531,"NA":3533},{"trials":3515,"activeCount":100},[3516],{"nctId":3517,"briefTitle":3518,"status":186,"phases":3519,"primaryCompletion":3520,"completion":3520,"start":3521,"enrollment":444,"conditions":3522,"interventions":3524},"NCT05075889","Utility of ICG in Benign Bone Tumors",[88],"2022-04-20","2021-11-11",[3523],"Bone Tumor",[3512],{"trials":3526,"activeCount":100},[],{"trials":3528,"activeCount":100},[],{"trials":3530,"activeCount":100},[],{"trials":3532,"activeCount":100},[],{"trials":3534,"activeCount":100},[],{"intervention":3536,"totalTrials":96,"cells":3537},"vincristine",{"EARLY_PHASE1":3538,"PHASE1":3547,"PHASE2":3549,"PHASE3":3551,"PHASE4":3553,"NA":3555},{"trials":3539,"activeCount":100},[3540],{"nctId":3541,"briefTitle":3542,"status":287,"phases":3543,"primaryCompletion":1384,"completion":1384,"start":2111,"enrollment":35,"conditions":3544,"interventions":3546},"NCT01463852","A Study of the Effect of Vinca Alkaloids on c-Jun N-terminal Kinase (JNK) Phosphorylation in Patients With Chronic Lymphocytic Leukemia (CLL)",[88],[3545],"Chronic Lymphocytic Leukemia (CLL)",[3536],{"trials":3548,"activeCount":100},[],{"trials":3550,"activeCount":100},[],{"trials":3552,"activeCount":100},[],{"trials":3554,"activeCount":100},[],{"trials":3556,"activeCount":100},[],{"intervention":3558,"totalTrials":96,"cells":3559},"Metformin",{"EARLY_PHASE1":3560,"PHASE1":3571,"PHASE2":3573,"PHASE3":3575,"PHASE4":3577,"NA":3579},{"trials":3561,"activeCount":100},[3562],{"nctId":3563,"briefTitle":3564,"status":287,"phases":3565,"primaryCompletion":3566,"completion":3566,"start":3567,"enrollment":313,"conditions":3568,"interventions":3570},"NCT03477162","Metformin Pharmacology in Human Cancers: A Proof of Principle Study",[88],"2021-11-30","2018-05-15",[3569],"Thoracic Neoplasm",[3558],{"trials":3572,"activeCount":100},[],{"trials":3574,"activeCount":100},[],{"trials":3576,"activeCount":100},[],{"trials":3578,"activeCount":100},[],{"trials":3580,"activeCount":100},[],{"intervention":1068,"totalTrials":149,"cells":3582},{"EARLY_PHASE1":3583,"PHASE1":3585,"PHASE2":3587,"PHASE3":3589,"PHASE4":3591,"NA":3608},{"trials":3584,"activeCount":100},[],{"trials":3586,"activeCount":100},[],{"trials":3588,"activeCount":100},[],{"trials":3590,"activeCount":100},[],{"trials":3592,"activeCount":100},[3593,3597],{"nctId":1059,"briefTitle":1060,"status":186,"phases":3594,"primaryCompletion":376,"completion":376,"start":1062,"enrollment":1063,"conditions":3595,"interventions":3596},[92],[15,1065,21,945,1066],[1068,1046],{"nctId":3598,"briefTitle":3599,"status":186,"phases":3600,"primaryCompletion":3601,"completion":3601,"start":3602,"enrollment":3603,"conditions":3604,"interventions":3606},"NCT01639872","Clozapine for Cannabis Use in Schizophrenia",[92],"2017-03-29","2013-05-01",49,[15,1066,3605,1065],"Cannabis Dependence",[1068,3607],"Risperidone",{"trials":3609,"activeCount":100},[3610],{"nctId":3611,"briefTitle":3612,"status":186,"phases":3613,"primaryCompletion":992,"completion":2849,"start":1454,"enrollment":9,"conditions":3614,"interventions":3617},"NCT00573287","First Episode Schizophrenia and Cannabis-Related Disorder Study",[93],[3615,3616,15,1229],"Cannabis-Related Disorder","Substance-Related Disorders",[3618,3619],"clozapine","risperidone",{"intervention":1987,"totalTrials":149,"cells":3621},{"EARLY_PHASE1":3622,"PHASE1":3624,"PHASE2":3630,"PHASE3":3632,"PHASE4":3645,"NA":3647},{"trials":3623,"activeCount":100},[],{"trials":3625,"activeCount":100},[3626],{"nctId":1979,"briefTitle":1980,"status":186,"phases":3627,"primaryCompletion":1982,"completion":1982,"start":1983,"enrollment":810,"conditions":3628,"interventions":3629},[89],[1985],[1972,1987],{"trials":3631,"activeCount":100},[],{"trials":3633,"activeCount":100},[3634],{"nctId":3635,"briefTitle":3636,"status":186,"phases":3637,"primaryCompletion":1982,"completion":1982,"start":3638,"enrollment":3639,"conditions":3640,"interventions":3644},"NCT00153803","Erlotinib or Placebo Following Chemoradiotherapy (Chemo\u002FRT) in Stage III Non-Small Cell Lung Cancer (NSCLC)",[91],"2005-05",245,[3641,3642,3643],"Carcinoma, Non-Small-Cell Lung","Non-small Cell Lung Cancer","NSCLC",[1987],{"trials":3646,"activeCount":100},[],{"trials":3648,"activeCount":100},[3649],{"nctId":3650,"briefTitle":3651,"status":186,"phases":3652,"primaryCompletion":188,"completion":188,"start":3653,"enrollment":32,"conditions":3654,"interventions":3655},"NCT00125372","Study of Tarceva and Targretin in Stage I-II Lung Cancer",[93],"2005-12",[1996],[3656],"erlotinib",{"intervention":3658,"totalTrials":149,"cells":3659},"Ketamine",{"EARLY_PHASE1":3660,"PHASE1":3674,"PHASE2":3676,"PHASE3":3686,"PHASE4":3688,"NA":3690},{"trials":3661,"activeCount":100},[3662],{"nctId":3663,"briefTitle":3664,"status":186,"phases":3665,"primaryCompletion":3666,"completion":3667,"start":3668,"enrollment":3669,"conditions":3670,"interventions":3673},"NCT04437888","Intraoperative Ketamine for Patients Undergoing Total Joint Arthroplasty",[88],"2024-04-05","2024-06-01","2020-09-14",200,[3671,3672],"Pain, Postoperative","Arthroplasty Complications",[3658],{"trials":3675,"activeCount":100},[],{"trials":3677,"activeCount":100},[3678],{"nctId":3679,"briefTitle":3680,"status":186,"phases":3681,"primaryCompletion":3682,"completion":3682,"start":290,"enrollment":35,"conditions":3683,"interventions":3685},"NCT01653327","Analgesic Effects of Topical Ketamine Mouthwash in Patients Receiving Chemoradiation or Radiotherapy for Head & Neck Cancer",[90],"2016-08-16",[3684,790],"Mucositis",[3658],{"trials":3687,"activeCount":100},[],{"trials":3689,"activeCount":100},[],{"trials":3691,"activeCount":100},[3692],{"nctId":3693,"briefTitle":3694,"status":186,"phases":3695,"primaryCompletion":2251,"completion":2251,"start":3696,"enrollment":3697,"conditions":3698,"interventions":3700},"NCT00899600","Intra-operative Ketamine Infusions in Opioid-dependent Patients With Chronic Lower Back Pain",[93],"2007-02",102,[3699],"Chronic Low Back Pain",[3658],{"intervention":3619,"totalTrials":444,"cells":3702},{"EARLY_PHASE1":3703,"PHASE1":3705,"PHASE2":3707,"PHASE3":3709,"PHASE4":3711,"NA":3717},{"trials":3704,"activeCount":100},[],{"trials":3706,"activeCount":100},[],{"trials":3708,"activeCount":100},[],{"trials":3710,"activeCount":100},[],{"trials":3712,"activeCount":100},[3713],{"nctId":3598,"briefTitle":3599,"status":186,"phases":3714,"primaryCompletion":3601,"completion":3601,"start":3602,"enrollment":3603,"conditions":3715,"interventions":3716},[92],[15,1066,3605,1065],[1068,3607],{"trials":3718,"activeCount":100},[3719],{"nctId":3611,"briefTitle":3612,"status":186,"phases":3720,"primaryCompletion":992,"completion":2849,"start":1454,"enrollment":9,"conditions":3721,"interventions":3722},[93],[3615,3616,15,1229],[3618,3619],{"intervention":3724,"totalTrials":444,"cells":3725},"Aprepitant",{"EARLY_PHASE1":3726,"PHASE1":3728,"PHASE2":3730,"PHASE3":3732,"PHASE4":3734,"NA":3736},{"trials":3727,"activeCount":100},[],{"trials":3729,"activeCount":100},[],{"trials":3731,"activeCount":100},[],{"trials":3733,"activeCount":100},[],{"trials":3735,"activeCount":100},[],{"trials":3737,"activeCount":100},[3738,3745],{"nctId":3739,"briefTitle":3740,"status":186,"phases":3741,"primaryCompletion":3742,"completion":3742,"start":1653,"enrollment":897,"conditions":3743,"interventions":3744},"NCT01854177","Differentiating the Effects of Substance P and Beta-endorphin",[93],"2013-11",[192],[3724],{"nctId":3746,"briefTitle":3747,"status":186,"phases":3748,"primaryCompletion":2868,"completion":2868,"start":3496,"enrollment":2687,"conditions":3749,"interventions":3750},"NCT01580423","The Role of Substance P on Perception of Breathlessness During Resistive Load Breathing",[93],[192],[3751],"aprepitant",{"intervention":2334,"totalTrials":444,"cells":3753},{"EARLY_PHASE1":3754,"PHASE1":3756,"PHASE2":3758,"PHASE3":3764,"PHASE4":3766,"NA":3768},{"trials":3755,"activeCount":100},[],{"trials":3757,"activeCount":100},[],{"trials":3759,"activeCount":100},[3760],{"nctId":2326,"briefTitle":2327,"status":186,"phases":3761,"primaryCompletion":2329,"completion":2330,"start":2331,"enrollment":995,"conditions":3762,"interventions":3763},[90],[380],[2317,2334,2335,2336],{"trials":3765,"activeCount":100},[],{"trials":3767,"activeCount":100},[],{"trials":3769,"activeCount":100},[3770],{"nctId":3771,"briefTitle":3772,"status":186,"phases":3773,"primaryCompletion":3774,"completion":3774,"start":1270,"enrollment":22,"conditions":3775,"interventions":3776},"NCT02010021","Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer.",[93],"2017-12-08",[18],[2334],{"intervention":318,"totalTrials":444,"cells":3778},{"EARLY_PHASE1":3779,"PHASE1":3781,"PHASE2":3787,"PHASE3":3789,"PHASE4":3791,"NA":3793},{"trials":3780,"activeCount":100},[],{"trials":3782,"activeCount":100},[3783],{"nctId":326,"briefTitle":327,"status":186,"phases":3784,"primaryCompletion":329,"completion":330,"start":331,"enrollment":276,"conditions":3785,"interventions":3786},[89],[333,334,335,219,336,337,338],[224,340,341,318],{"trials":3788,"activeCount":100},[],{"trials":3790,"activeCount":100},[],{"trials":3792,"activeCount":100},[],{"trials":3794,"activeCount":100},[3795],{"nctId":308,"briefTitle":309,"status":186,"phases":3796,"primaryCompletion":311,"completion":311,"start":312,"enrollment":313,"conditions":3797,"interventions":3798},[93],[267],[316,224,282,317,318],{"intervention":3800,"totalTrials":444,"cells":3801},"Morphine",{"EARLY_PHASE1":3802,"PHASE1":3804,"PHASE2":3806,"PHASE3":3808,"PHASE4":3810,"NA":3812},{"trials":3803,"activeCount":100},[],{"trials":3805,"activeCount":100},[],{"trials":3807,"activeCount":100},[],{"trials":3809,"activeCount":100},[],{"trials":3811,"activeCount":100},[],{"trials":3813,"activeCount":100},[3814,3824],{"nctId":3815,"briefTitle":3816,"status":186,"phases":3817,"completion":3818,"start":3696,"enrollment":3819,"conditions":3820,"interventions":3822},"NCT00504283","An Analgesia Protocol for Acute Renal Colic in the Emergency Department",[93],"2007-10",45,[3821],"Kidney Stone",[3823,3800],"Toradol",{"nctId":3825,"briefTitle":3826,"status":160,"phases":3827,"primaryCompletion":1982,"completion":1982,"start":1982,"enrollment":100,"conditions":3828,"interventions":3830},"NCT02091297","Comparison of Different Methods of Pain Control After Cesarean Section for Patients on Buprenorphine or Methadone",[93],[3829],"Caesarean Delivery",[3831,3832,3833,3800],"TAP Block","Ropivacaine","Acetaminophen",{"intervention":3835,"totalTrials":96,"cells":3836},"Melphalan",{"EARLY_PHASE1":3837,"PHASE1":3839,"PHASE2":3841,"PHASE3":3843,"PHASE4":3845,"NA":3847},{"trials":3838,"activeCount":100},[],{"trials":3840,"activeCount":100},[],{"trials":3842,"activeCount":100},[],{"trials":3844,"activeCount":100},[],{"trials":3846,"activeCount":100},[],{"trials":3848,"activeCount":100},[3849],{"nctId":3850,"briefTitle":3851,"status":186,"phases":3852,"primaryCompletion":273,"completion":273,"start":3853,"enrollment":19,"conditions":3854,"interventions":3856},"NCT00789256","Low Dose Melphalan and Bortezomib for AML and High-Risk MDS",[93],"2004-09",[3855,335],"Acute Myelogenous Leukemia",[3835,3857,3858],"Bortezomib","Melphalan and bortezomib",{"intervention":3857,"totalTrials":96,"cells":3860},{"EARLY_PHASE1":3861,"PHASE1":3863,"PHASE2":3865,"PHASE3":3867,"PHASE4":3869,"NA":3871},{"trials":3862,"activeCount":100},[],{"trials":3864,"activeCount":100},[],{"trials":3866,"activeCount":100},[],{"trials":3868,"activeCount":100},[],{"trials":3870,"activeCount":100},[],{"trials":3872,"activeCount":100},[3873],{"nctId":3850,"briefTitle":3851,"status":186,"phases":3874,"primaryCompletion":273,"completion":273,"start":3853,"enrollment":19,"conditions":3875,"interventions":3876},[93],[3855,335],[3835,3857,3858],{"intervention":3858,"totalTrials":96,"cells":3878},{"EARLY_PHASE1":3879,"PHASE1":3881,"PHASE2":3883,"PHASE3":3885,"PHASE4":3887,"NA":3889},{"trials":3880,"activeCount":100},[],{"trials":3882,"activeCount":100},[],{"trials":3884,"activeCount":100},[],{"trials":3886,"activeCount":100},[],{"trials":3888,"activeCount":100},[],{"trials":3890,"activeCount":100},[3891],{"nctId":3850,"briefTitle":3851,"status":186,"phases":3892,"primaryCompletion":273,"completion":273,"start":3853,"enrollment":19,"conditions":3893,"interventions":3894},[93],[3855,335],[3835,3857,3858],{"intervention":194,"totalTrials":96,"cells":3896},{"EARLY_PHASE1":3897,"PHASE1":3899,"PHASE2":3901,"PHASE3":3903,"PHASE4":3905,"NA":3907},{"trials":3898,"activeCount":100},[],{"trials":3900,"activeCount":100},[],{"trials":3902,"activeCount":100},[],{"trials":3904,"activeCount":100},[],{"trials":3906,"activeCount":100},[],{"trials":3908,"activeCount":100},[3909],{"nctId":184,"briefTitle":185,"status":186,"phases":3910,"primaryCompletion":188,"completion":189,"start":190,"enrollment":9,"conditions":3911,"interventions":3912},[93],[192],[194,195],{"intervention":3914,"totalTrials":96,"cells":3915},"Vorinostat",{"EARLY_PHASE1":3916,"PHASE1":3918,"PHASE2":3920,"PHASE3":3922,"PHASE4":3924,"NA":3926},{"trials":3917,"activeCount":100},[],{"trials":3919,"activeCount":100},[],{"trials":3921,"activeCount":100},[],{"trials":3923,"activeCount":100},[],{"trials":3925,"activeCount":100},[],{"trials":3927,"activeCount":100},[3928],{"nctId":3929,"briefTitle":3930,"status":186,"phases":3931,"primaryCompletion":3932,"completion":3932,"start":376,"enrollment":897,"conditions":3933,"interventions":3935},"NCT00735826","A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Aerodigestive Tract Cancer",[93],"2012-07",[3934,1847,1845,790],"Aerodigestive Tract Cancer",[3914],{"intervention":3937,"totalTrials":96,"cells":3938},"62% ethanol based hand cleanser",{"EARLY_PHASE1":3939,"PHASE1":3941,"PHASE2":3943,"PHASE3":3945,"PHASE4":3947,"NA":3949},{"trials":3940,"activeCount":100},[],{"trials":3942,"activeCount":100},[],{"trials":3944,"activeCount":100},[],{"trials":3946,"activeCount":100},[],{"trials":3948,"activeCount":100},[],{"trials":3950,"activeCount":100},[3951],{"nctId":3952,"briefTitle":3953,"status":186,"phases":3954,"primaryCompletion":2912,"completion":993,"start":3955,"enrollment":3956,"conditions":3957,"interventions":3959},"NCT01050608","Evaluation of Body-worn Multimodal Hand Hygiene System. Impact on Health-Care Associated Infections",[],"2007-12",2954,[3958],"Nosocomial Infection",[3937],{"intervention":3961,"totalTrials":96,"cells":3962},"mifepristone",{"EARLY_PHASE1":3963,"PHASE1":3965,"PHASE2":3967,"PHASE3":3969,"PHASE4":3971,"NA":3973},{"trials":3964,"activeCount":100},[],{"trials":3966,"activeCount":100},[],{"trials":3968,"activeCount":100},[],{"trials":3970,"activeCount":100},[],{"trials":3972,"activeCount":100},[],{"trials":3974,"activeCount":100},[3975],{"nctId":3976,"briefTitle":3977,"status":186,"phases":3978,"completion":1454,"start":1335,"enrollment":1481,"conditions":3979,"interventions":3981},"NCT00383032","Mifepristone Versus Laminaria for Cervical Ripening in Midtrimester Induction",[93],[3980],"Abortion, Induced",[3961],{"intervention":3983,"totalTrials":96,"cells":3984},"arformoterol",{"EARLY_PHASE1":3985,"PHASE1":3987,"PHASE2":3989,"PHASE3":3991,"PHASE4":3993,"NA":3995},{"trials":3986,"activeCount":100},[],{"trials":3988,"activeCount":100},[],{"trials":3990,"activeCount":100},[],{"trials":3992,"activeCount":100},[],{"trials":3994,"activeCount":100},[],{"trials":3996,"activeCount":100},[3997],{"nctId":3998,"briefTitle":3999,"status":186,"phases":4000,"primaryCompletion":2111,"completion":2111,"start":4001,"enrollment":276,"conditions":4002,"interventions":4003},"NCT01391559","Efficacy of Inhaling Bronchodilator Medications in Chronic Obstructive Pulmonary Disease",[93],"2011-07",[192],[3983,4004],"salmeterol",{"intervention":4004,"totalTrials":96,"cells":4006},{"EARLY_PHASE1":4007,"PHASE1":4009,"PHASE2":4011,"PHASE3":4013,"PHASE4":4015,"NA":4017},{"trials":4008,"activeCount":100},[],{"trials":4010,"activeCount":100},[],{"trials":4012,"activeCount":100},[],{"trials":4014,"activeCount":100},[],{"trials":4016,"activeCount":100},[],{"trials":4018,"activeCount":100},[4019],{"nctId":3998,"briefTitle":3999,"status":186,"phases":4020,"primaryCompletion":2111,"completion":2111,"start":4001,"enrollment":276,"conditions":4021,"interventions":4022},[93],[192],[3983,4004],{"intervention":4024,"totalTrials":96,"cells":4025},"Methylphenidate",{"EARLY_PHASE1":4026,"PHASE1":4028,"PHASE2":4030,"PHASE3":4032,"PHASE4":4034,"NA":4036},{"trials":4027,"activeCount":100},[],{"trials":4029,"activeCount":100},[],{"trials":4031,"activeCount":100},[],{"trials":4033,"activeCount":100},[],{"trials":4035,"activeCount":100},[],{"trials":4037,"activeCount":100},[4038],{"nctId":4039,"briefTitle":4040,"status":186,"phases":4041,"primaryCompletion":4042,"completion":4042,"start":3696,"enrollment":4043,"conditions":4044,"interventions":4046},"NCT00453921","Methylphenidate (Ritalin) and Memory\u002FAttention in Traumatic Brain Injury (TBI)",[93],"2013-05",76,[4045],"Brain Injury",[4024],{"intervention":4048,"totalTrials":96,"cells":4049},"Ferrous sulfate 325mg",{"EARLY_PHASE1":4050,"PHASE1":4052,"PHASE2":4054,"PHASE3":4056,"PHASE4":4058,"NA":4060},{"trials":4051,"activeCount":100},[],{"trials":4053,"activeCount":100},[],{"trials":4055,"activeCount":100},[],{"trials":4057,"activeCount":100},[],{"trials":4059,"activeCount":100},[],{"trials":4061,"activeCount":100},[4062],{"nctId":4063,"briefTitle":4064,"status":186,"phases":4065,"primaryCompletion":4066,"completion":4066,"start":1294,"enrollment":4067,"conditions":4068,"interventions":4071},"NCT01755455","Does a Daily Iron Tablet Improve Anemia in Cystic Fibrosis",[93],"2012-11",22,[4069,4070],"Cystic Fibrosis","Anemia, Iron-Deficiency",[4048],{"intervention":4073,"totalTrials":96,"cells":4074},"naloxone versus placebo",{"EARLY_PHASE1":4075,"PHASE1":4077,"PHASE2":4079,"PHASE3":4081,"PHASE4":4083,"NA":4085},{"trials":4076,"activeCount":100},[],{"trials":4078,"activeCount":100},[],{"trials":4080,"activeCount":100},[],{"trials":4082,"activeCount":100},[],{"trials":4084,"activeCount":100},[],{"trials":4086,"activeCount":100},[4087],{"nctId":4088,"briefTitle":4089,"status":186,"phases":4090,"completion":1784,"start":404,"enrollment":22,"conditions":4091,"interventions":4092},"NCT00458419","Role of Endorphins in the Perception of Dyspnea in Patients With Chronic Obstructive Pulmonary Disease",[93],[192],[4073,4093],"intravenous injection of normal saline or naloxone",{"intervention":4093,"totalTrials":96,"cells":4095},{"EARLY_PHASE1":4096,"PHASE1":4098,"PHASE2":4100,"PHASE3":4102,"PHASE4":4104,"NA":4106},{"trials":4097,"activeCount":100},[],{"trials":4099,"activeCount":100},[],{"trials":4101,"activeCount":100},[],{"trials":4103,"activeCount":100},[],{"trials":4105,"activeCount":100},[],{"trials":4107,"activeCount":100},[4108],{"nctId":4088,"briefTitle":4089,"status":186,"phases":4109,"completion":1784,"start":404,"enrollment":22,"conditions":4110,"interventions":4111},[93],[192],[4073,4093],{"intervention":4113,"totalTrials":96,"cells":4114},"Hydrocortisone",{"EARLY_PHASE1":4115,"PHASE1":4117,"PHASE2":4119,"PHASE3":4121,"PHASE4":4123,"NA":4125},{"trials":4116,"activeCount":100},[],{"trials":4118,"activeCount":100},[],{"trials":4120,"activeCount":100},[],{"trials":4122,"activeCount":100},[],{"trials":4124,"activeCount":100},[],{"trials":4126,"activeCount":100},[4127],{"nctId":4128,"briefTitle":4129,"status":186,"phases":4130,"primaryCompletion":1817,"completion":1817,"start":2663,"enrollment":495,"conditions":4131,"interventions":4133},"NCT00396344","Cortisol Control of Human Inflammatory Responses to Endotoxin",[93],[4132],"Sepsis",[4113,4113],{"intervention":4135,"totalTrials":96,"cells":4136},"Cefazolin",{"EARLY_PHASE1":4137,"PHASE1":4139,"PHASE2":4141,"PHASE3":4143,"PHASE4":4145,"NA":4147},{"trials":4138,"activeCount":100},[],{"trials":4140,"activeCount":100},[],{"trials":4142,"activeCount":100},[],{"trials":4144,"activeCount":100},[],{"trials":4146,"activeCount":100},[],{"trials":4148,"activeCount":100},[4149],{"nctId":4150,"briefTitle":4151,"status":160,"phases":4152,"primaryCompletion":4153,"completion":4154,"start":4155,"enrollment":100,"conditions":4156,"interventions":4158},"NCT05304871","Randomized Assessment of Antibiotic Prophylaxis Prior to Port Placement",[93],"2027-03","2027-12","2024-01",[4157],"Vascular Access Ports",[4135],{"intervention":317,"totalTrials":96,"cells":4160},{"EARLY_PHASE1":4161,"PHASE1":4163,"PHASE2":4165,"PHASE3":4167,"PHASE4":4169,"NA":4171},{"trials":4162,"activeCount":100},[],{"trials":4164,"activeCount":100},[],{"trials":4166,"activeCount":100},[],{"trials":4168,"activeCount":100},[],{"trials":4170,"activeCount":100},[],{"trials":4172,"activeCount":100},[4173],{"nctId":308,"briefTitle":309,"status":186,"phases":4174,"primaryCompletion":311,"completion":311,"start":312,"enrollment":313,"conditions":4175,"interventions":4176},[93],[267],[316,224,282,317,318],{"intervention":4178,"totalTrials":96,"cells":4179},"Indocyanine green solution",{"EARLY_PHASE1":4180,"PHASE1":4182,"PHASE2":4184,"PHASE3":4186,"PHASE4":4188,"NA":4190},{"trials":4181,"activeCount":100},[],{"trials":4183,"activeCount":100},[],{"trials":4185,"activeCount":100},[],{"trials":4187,"activeCount":100},[],{"trials":4189,"activeCount":100},[],{"trials":4191,"activeCount":100},[4192],{"nctId":4193,"briefTitle":4194,"status":186,"phases":4195,"primaryCompletion":4196,"completion":4196,"start":4197,"enrollment":313,"conditions":4198,"interventions":4200},"NCT04839302","Detection and Delineation of Necrotizing Fasciitis Via a Vascular Perfusion Fluorophore",[],"2024-12-04","2021-04-05",[4199],"Necrotising Fasciitis",[4178],{"intervention":3823,"totalTrials":96,"cells":4202},{"EARLY_PHASE1":4203,"PHASE1":4205,"PHASE2":4207,"PHASE3":4209,"PHASE4":4211,"NA":4213},{"trials":4204,"activeCount":100},[],{"trials":4206,"activeCount":100},[],{"trials":4208,"activeCount":100},[],{"trials":4210,"activeCount":100},[],{"trials":4212,"activeCount":100},[],{"trials":4214,"activeCount":100},[4215],{"nctId":3815,"briefTitle":3816,"status":186,"phases":4216,"completion":3818,"start":3696,"enrollment":3819,"conditions":4217,"interventions":4218},[93],[3821],[3823,3800],{"intervention":4220,"totalTrials":96,"cells":4221},"TOBI™ Podhaler™ 112 mg inhaled twice daily",{"EARLY_PHASE1":4222,"PHASE1":4224,"PHASE2":4226,"PHASE3":4228,"PHASE4":4230,"NA":4232},{"trials":4223,"activeCount":100},[],{"trials":4225,"activeCount":100},[],{"trials":4227,"activeCount":100},[],{"trials":4229,"activeCount":100},[],{"trials":4231,"activeCount":100},[],{"trials":4233,"activeCount":100},[4234],{"nctId":4235,"briefTitle":4236,"status":287,"phases":4237,"primaryCompletion":2935,"completion":2935,"start":1982,"enrollment":96,"conditions":4238,"interventions":4239},"NCT02113397","Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung",[],[4069],[4220,4240],"Colistimethate 75 mg inhaled two times daily",{"intervention":4240,"totalTrials":96,"cells":4242},{"EARLY_PHASE1":4243,"PHASE1":4245,"PHASE2":4247,"PHASE3":4249,"PHASE4":4251,"NA":4253},{"trials":4244,"activeCount":100},[],{"trials":4246,"activeCount":100},[],{"trials":4248,"activeCount":100},[],{"trials":4250,"activeCount":100},[],{"trials":4252,"activeCount":100},[],{"trials":4254,"activeCount":100},[4255],{"nctId":4235,"briefTitle":4236,"status":287,"phases":4256,"primaryCompletion":2935,"completion":2935,"start":1982,"enrollment":96,"conditions":4257,"interventions":4258},[],[4069],[4220,4240],{"intervention":3831,"totalTrials":96,"cells":4260},{"EARLY_PHASE1":4261,"PHASE1":4263,"PHASE2":4265,"PHASE3":4267,"PHASE4":4269,"NA":4271},{"trials":4262,"activeCount":100},[],{"trials":4264,"activeCount":100},[],{"trials":4266,"activeCount":100},[],{"trials":4268,"activeCount":100},[],{"trials":4270,"activeCount":100},[],{"trials":4272,"activeCount":100},[4273],{"nctId":3825,"briefTitle":3826,"status":160,"phases":4274,"primaryCompletion":1982,"completion":1982,"start":1982,"enrollment":100,"conditions":4275,"interventions":4276},[93],[3829],[3831,3832,3833,3800],{"intervention":3832,"totalTrials":96,"cells":4278},{"EARLY_PHASE1":4279,"PHASE1":4281,"PHASE2":4283,"PHASE3":4285,"PHASE4":4287,"NA":4289},{"trials":4280,"activeCount":100},[],{"trials":4282,"activeCount":100},[],{"trials":4284,"activeCount":100},[],{"trials":4286,"activeCount":100},[],{"trials":4288,"activeCount":100},[],{"trials":4290,"activeCount":100},[4291],{"nctId":3825,"briefTitle":3826,"status":160,"phases":4292,"primaryCompletion":1982,"completion":1982,"start":1982,"enrollment":100,"conditions":4293,"interventions":4294},[93],[3829],[3831,3832,3833,3800],{"intervention":3833,"totalTrials":96,"cells":4296},{"EARLY_PHASE1":4297,"PHASE1":4299,"PHASE2":4301,"PHASE3":4303,"PHASE4":4305,"NA":4307},{"trials":4298,"activeCount":100},[],{"trials":4300,"activeCount":100},[],{"trials":4302,"activeCount":100},[],{"trials":4304,"activeCount":100},[],{"trials":4306,"activeCount":100},[],{"trials":4308,"activeCount":100},[4309],{"nctId":3825,"briefTitle":3826,"status":160,"phases":4310,"primaryCompletion":1982,"completion":1982,"start":1982,"enrollment":100,"conditions":4311,"interventions":4312},[93],[3829],[3831,3832,3833,3800],{"intervention":4314,"totalTrials":96,"cells":4315},"Pegfilgrastim",{"EARLY_PHASE1":4316,"PHASE1":4318,"PHASE2":4320,"PHASE3":4322,"PHASE4":4324,"NA":4326},{"trials":4317,"activeCount":100},[],{"trials":4319,"activeCount":100},[],{"trials":4321,"activeCount":100},[],{"trials":4323,"activeCount":100},[],{"trials":4325,"activeCount":100},[],{"trials":4327,"activeCount":100},[4328],{"nctId":4329,"briefTitle":4330,"status":287,"phases":4331,"primaryCompletion":4332,"completion":4332,"start":1408,"enrollment":291,"conditions":4333,"interventions":4334},"NCT00689884","Feasibility and Cost Analysis of PBSC Mobilization Using Pegfilgrastim in Hematologic Malignancies",[93],"2009-01",[267],[4314]]